

---

**Clinical Study Protocol**

Drug Substance	Acalabrutinib
Study Code	ACE-ID-201 (D822FC00001)
Version	3.0
Date	28Apr2020

---

---

**A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19**

---

**Sponsor:**

Acerta Pharma B.V., a Dutch limited liability company, whose registered office is at Kloosterstraat 9, 5349 AB, Oss, The Netherlands, a member of the AstraZeneca group (“Company”)

IND# 149513

EudraCT# 2020-001644-25

## PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE

DOCUMENT HISTORY	
Document	Date
Amendment 2 (Version 3.0)	28Apr2020
Amendment 1 (Version 2.0)	17Apr2020
Original Protocol (Version 1.0)	05Apr2020

### **Amendment 2 (28Apr2020)**

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

### **Overall Rationale for the Amendment:**

The overall rationale for the amendment was to remove Part 2 of the study based on Health Authority feedback.

Section # and Name	Description of Change	Brief Rationale
Title Page	Removed ACE-ID-201 and kept D822FC00001 as study number	D822FC00001 is the new study number
1.1 Schedule of Activities (SoA)	Revised Table 1 for clarity and consistency with the protocol body	Clarity and consistency
1.2 Synopsis; 2.1 Background and Study Rationale	Added a statement on clinical outcomes with Btk inhibitors for COVID-19 from a recent report	To further support the rationale for using Btk inhibitors for COVID-19
1.2 Synopsis; 1.3 Schema; 3 Objectives and Endpoints; 4.1 Overall Design; 4.2 Scientific Rationale for Study Design; 4.4 Internal DMC; 5 Study Population; 6.1 Treatments administered; 9.1 Statistical Hypotheses; 9.2 Sample Size Determination; 9.6.1 Safety Analyses; 9.6.2 Efficacy Analyses	Revised sections throughout protocol to reflect removal of Part 2 from the study	In response to Health Authority feedback

Section # and Name	Description of Change	Brief Rationale
1.2 Synopsis; 3 Objectives and Endpoints	Split the safety and PK objectives/endpoints. Added Days 14 and 28 to C-reactive protein and ferritin secondary endpoints and added Day 28 to the absolute lymphocyte counts secondary endpoint.	Clarity and completeness
4.5 End of Study Definition	Added that all randomized subjects will be followed for survival through 90 ( $\pm$ 7) days after randomization	Clarity
5.1 Inclusion Criteria	Added Inclusion Criterion 5 (ability to swallow pills)	To align with feedback received from health authorities
5.2 Exclusion Criteria	Added sub-headers to group the different exclusion criteria. Revised Exclusion Criteria 1, 2, 7, 8, 17, 18, 20, and 21	For clarity and to align with feedback received from healthy authorities
5.3 Screen Failures	Specified that the minimal set of screen failure information to be collected will be unrelated to the disease under investigation	Clarity
6 Study Treatments	Made revisions throughout this section.	For clarity and to be more informative.
7.1 Discontinuation of Study Treatment	Replaced “respiratory failure” with “unable to swallow pills” as a reason for treatment discontinuation	If subjects can still swallow pills they should be allowed to continue treatment since expectation that benefit of treatment may still be possible
	Removed the statement, “Subject who permanently discontinue treatment should be given locally available standard of care therapy, at the discretion of the investigator”	To avoid confusion as subjects already receive best supportive care
	Added that all subjects will be followed through 90 (+ 7) days after randomization	Clarity
7.3 Lost to Follow-up	Added a statement to indicate that site personnel should check hospital records, public registries, and subject’s current physician to determine the reason for discontinuation when a subject is lost to follow-up	For completeness

Section # and Name	Description of Change	Brief Rationale
8.1 Screening Assessments; 8.3 On-study Procedures; 8.4 Clinical Assessments During Hospitalization	Revised for clarity and to align with the Schedule of Assessments	Clarity and consistency
8.2 Concomitant Medications	Added that the reason for treatment should be captured as “disease under study” and medications used as BSC should be captured as concomitant medications	Clarity
8.6 Collection of Adverse Events	For progression of underlying disease, specified underlying disease “related to COVID-19 pneumonia (such as worsening of respiratory status or complications of pneumonia)”	Clarity
8.6.2 Time Period and Frequency for Collecting AE and SAE Information	Revised for clarity and to align with the Schedule of Assessments	Clarity and consistency
8.6.4 Adverse Event Data Collection	Specified that grading scales found in the revised NCI CTCAE Version 5.0 will be utilized for all events with an assigned CTCAE grading	Clarity
8.6.9 Disease Under Study; 8.6.10 Disease Progression	Specified that disease under study refers to “COVID-19 pneumonia and respiratory illness”	Clarity
9.6.1 Safety Analyses	Clarified the definition for treatment-emergent adverse events	Clarity
10 References	Added a new reference and removed references not cited in the protocol	Consistency
Appendix A, Section A 10 Publication Policy	Revised for clarity	Clarity
Appendix B, Section B 2 Definition of Serious Adverse Events	Removed text regarding malignant tumors	Not relevant to this study population
Appendix D Actions Required in Cases of Increases in Liver Biochemistry and Elevation of Hy’s Law	Revised appendix to be consistent with current protocol template language for Hy’s Law.	Consistency
Appendix G Child-Pugh Score	Added Appendix G	To support Exclusion Criterion 8

## TABLE OF CONTENTS

TITLE PAGE .....	1
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE .....	2
TABLE OF CONTENTS .....	5
1. PROTOCOL SUMMARY .....	9
1.1 Schedule of Activities (SoA).....	9
1.2 Synopsis .....	13
1.3 Schema .....	17
2. INTRODUCTION .....	19
2.1 Background and Study Rationale .....	19
2.2 Benefit/Risk Assessment.....	20
3. OBJECTIVES AND ENDPOINTS .....	21
4. STUDY DESIGN .....	23
4.1 Overall Design .....	23
4.2 Scientific Rationale for Study Design.....	24
4.3 Justification for Dose .....	24
4.4 Internal DMC.....	24
4.5 End of Study Definition .....	25
5. STUDY POPULATION .....	25
5.1 Inclusion Criteria .....	25
5.2 Exclusion Criteria .....	26
5.3 Screen Failures .....	28
6. STUDY TREATMENTS .....	28
6.1 Treatments Administered .....	28
6.2 Acalabrutinib Preparation/Handling/Storage/Accountability .....	29
6.3 Measures to Minimise Bias: Randomisation and Blinding.....	29
6.3.1 Subject Enrollment and Randomization.....	30
6.3.1.1 Procedures for Handling Incorrectly Enrolled or Randomized Subjects .....	30
6.3.1.2 Methods for Assigning Treatment Groups.....	31
6.3.1.3 Methods for Ensuring Blinding .....	31
6.4 Treatment Compliance .....	31
6.5 Concomitant Therapy.....	31
6.5.1 Premedications.....	31
6.5.2 Permitted Concomitant Therapy.....	32
6.5.3 Prohibited or Restricted Concomitant Therapy .....	32
6.5.3.1 Medications Prohibited for Subjects Treated with Acalabrutinib .....	32
6.5.3.2 Medications Prohibited for All Randomized Subjects.....	32

6.5.4	Acalabrutinib Drug-Drug Interaction Guidance in the Presence of Life-threatening COVID-19 Infection .....	33
6.5.4.1	Active Substances That May Increase Acalabrutinib Plasma Concentrations.....	33
6.5.4.2	Active Substances That May Decrease Acalabrutinib Plasma Concentrations....	34
6.6	Risks Associated with Acalabrutinib .....	34
6.6.1	Hemorrhage .....	35
6.6.2	Infections .....	35
6.6.3	Hepatitis B Reactivation.....	35
6.6.4	Progressive Multifocal Leukoencephalopathy .....	35
6.6.5	Cytopenias .....	35
6.6.6	Second Primary Malignancies .....	36
6.6.7	Atrial Fibrillation .....	36
6.6.8	Reference Safety Information.....	36
6.7	Dose Modification and Toxicity Management.....	36
6.7.1	Renal Impairment .....	37
6.7.2	Hepatic Impairment .....	37
6.8	Treatment After the End of Study.....	38
7.	DISCONTINUATION OF TREATMENT AND SUBJECT WITHDRAWAL .	38
7.1	Discontinuation of Study Treatment.....	38
7.2	Subject Withdrawal from the Study.....	39
7.3	Lost to Follow-Up.....	39
8.	STUDY ASSESSMENTS AND PROCEDURES.....	40
8.1	Screening Assessments .....	40
8.1.1	Informed Consent .....	40
8.1.2	Demographics .....	40
8.1.3	Confirmation of Eligibility.....	40
8.1.4	Medical History .....	41
8.1.5	Physical Examinations and Chest Imaging, Electrocardiogram, and Echocardiogram.....	41
8.1.6	Vital Signs .....	41
8.1.7	Urine or Serum Pregnancy .....	41
8.1.8	Laboratory Tests .....	42
8.2	Concomitant Medications .....	42
8.3	On-study Procedures.....	43
8.4	Clinical Assessments During Hospitalization .....	44
8.4.1	Oxygen Treatments and Ventilator Use.....	44
8.4.2	Modified Sequential Organ Failure Assessment (SOFA) Scores.....	44
8.4.3	Assessment of Number of Days in ICU.....	44
8.5	Follow Up Procedures.....	44
8.6	Collection of Adverse Events.....	45
8.6.1	Method of Detecting AEs and SAEs .....	46
8.6.2	Time Period and Frequency for Collecting AE and SAE Information.....	46
8.6.3	Follow-up of AEs and SAEs .....	46

8.6.4	Adverse Event Data Collection .....	46
8.6.5	Causality Collection.....	47
8.6.6	Adverse Events Based on Signs and Symptoms .....	48
8.6.7	Adverse Events Based on Examinations and Tests .....	48
8.6.8	Hy's Law .....	48
8.6.9	Disease Under Study .....	48
8.6.10	Disease Progression .....	49
8.6.11	Deaths.....	49
8.6.12	Adverse Events of Special Interest .....	49
8.7	Safety Reporting and Medical Management .....	50
8.7.1	Reporting of Serious Adverse Events .....	50
8.7.2	Pregnancy .....	51
8.7.2.1	Maternal Exposure .....	51
8.7.2.2	Paternal Exposure .....	51
8.7.3	Overdose.....	52
8.7.4	Medication Error.....	52
9.	STATISTICAL CONSIDERATIONS.....	53
9.1	Statistical Hypotheses .....	53
9.2	Sample Size Determination.....	53
9.3	Populations for Analyses.....	53
9.4	Interim Analysis.....	54
9.5	Missing Data Handling .....	54
9.6	Statistical Analyses .....	55
9.6.1	Safety Analyses .....	55
9.6.2	Efficacy Analyses .....	56
9.6.3	Pharmacokinetic and Pharmacodynamic Analyses .....	57
10.	REFERENCES .....	57

## LIST OF TABLES

Table 1	Schedule of Activities .....	10
Table 2	Protocol Objectives and Endpoints.....	21
Table 3	Acalabrutinib Use with Moderate CYP3A Inhibitors and Gastric Acid Reducing Agents.....	33
Table 4	Analysis Populations.....	54
Table 5	IATA Dangerous Goods Regulations Classification of Infectious Substances .....	71
Table 6	CYP3A Inhibitors .....	77
Table 7	CYP3A Inducers.....	78
Table 8	Other Drugs Needing Additional Considerations.....	78

Table 9	Highly Effective Methods of Contraception (<1% Failure Rate).....	80
Table 10	Child-Pugh Classification of Cirrhosis Severity .....	81

## LIST OF FIGURES

Figure 1	Study Design .....	18
----------	--------------------	----

## LIST OF APPENDICES

<b>Appendix A</b>	Regulatory, Ethical and Study Oversight Considerations.....	60
<b>Appendix B</b>	Adverse Event Definitions and Additional Safety Information .....	65
<b>Appendix C</b>	Handling of Human Biological Samples .....	69
<b>Appendix D</b>	Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy's Law .....	72
<b>Appendix E</b>	Examples of Coadministered Drugs That Need Additional Consideration	77
<b>Appendix F</b>	Contraception Requirements .....	79
<b>Appendix G</b>	Child-Pugh Score.....	81
<b>Appendix H</b>	Abbreviations .....	82
<b>Appendix I</b>	Protocol Amendment History.....	85

## **1.        PROTOCOL SUMMARY**

### **1.1       Schedule of Activities (SoA)**

The SoA for the study is presented in [Table 1](#).

**Table 1 Schedule of Activities**

Assessments	Screening (Day -1 or Day 1 <sup>a</sup> )	Daily until hospital discharge	Day 10 or discharge <sup>h</sup>	Day 14 (±2 days) after randomization	Day 28 (±3 days) after randomization	Safety FU 28 (±3) days after last dose of acalabrutinib <sup>l,m</sup>	Long-term FU 90 (±7) days after randomization <sup>j,k</sup>	CSP section
Informed consent	X							8.1.1
Demography	X							8.1.2
Determine eligibility	X							5.1, 5.2
Medical history and COVID-19 epidemiology	X							8.1.4
Physical examination (symptom driven, including lung auscultation), height, weight	X							8.1.5
Chest imaging	X	As clinically indicated						8.1.5
Electrocardiogram	X	As clinically indicated	X					8.1.5
Echocardiogram	As clinically indicated	As clinically indicated						8.1.5
Vital signs (blood pressure, respiratory rate, oximetry, pulse and body temperature)	X	X		X	X			8.1.6
Arterial blood gases (if available)	X	X		X	X			8.1.6, 8.1.8
Local laboratory assessments:								
Urine or serum pregnancy test (for WOCBP only)	X			X		X		8.1.7
Hematology <sup>b</sup>	X	X	X	X	X	X		8.1.8, 8.3
Serum or plasma chemistry <sup>c</sup>	X	X	X	X	X	X		8.1.8, 8.3
Hepatitis B and C testing <sup>d</sup>	X	As clinically indicated				As clinically indicated		6.6.3, 8.1.8, 8.3
Serum ferritin	X	X		X	X			8.1.8, 8.3

**Table 1 Schedule of Activities**

Assessments	Screening (Day -1 or Day 1 <sup>a</sup> )	Daily until hospital discharge	Day 10 or discharge <sup>h</sup>	Day 14 (±2 days) after randomization	Day 28 (±3 days) after randomization	Safety FU 28 (±3) days after last dose of acalabrutinib <sup>l,m</sup>	Long-term FU 90 (±7) days after randomization <sup>j,k</sup>	CSP section
Fibrinogen	X	X						8.1.8, 8.3
PT, aPTT, and INR	X	X						8.1.8, 8.3
D-dimer	X	X		X	X			8.1.8, 8.3
C-reactive protein (CRP)	X	X		X	X			8.1.8, 8.3
Procalcitonin (if available)	X	X		X	X			8.1.8, 8.3
Cardiac troponin I and BNP	X	X						8.1.8, 8.3
SARS-CoV-2 RT-PCR virus testing for eligibility <sup>e</sup>	Within 4 days prior to randomi- zation							8.1.8, 5.1
Clinical assessments		As applicable until hospital discharge						8.4
Central laboratory assessments								
Correlative samples <sup>a</sup>	X	Days 3 and 7	X	X	X			8.1.8, 8.3
Serum sample <sup>a,f</sup>		Days 3 and 7	X					8.1.8, 8.3
Immunophenotyping <sup>a,g</sup>	X	Days 3 and 7	X	X	X			8.1.8, 8.3
SARS-CoV-2 viral load/viral shedding <sup>a</sup>	X	Days 3 and 7	X	X	X			8.1.8, 8.3
Serum sample (SARS-CoV-2 quantitative serology) <sup>a,f</sup>	X			X	X			8.1.8, 8.3
Acalabrutinib pharmacodynamics <sup>a</sup>	Predose and 4 hours postdose on Day1	Predose and 4 hours postdose on Days 3 and 7	X <sup>a</sup>	X <sup>a</sup>				8.3
Acalabrutinib pharmacokinetics		Predose, 0.5, 1, 2, 4, and 6 hours postdose on Day 3						8.3

**Table 1 Schedule of Activities**

Assessments	Screening (Day -1 or Day 1 <sup>a</sup> )	Daily until hospital discharge	Day 10 or discharge <sup>h</sup>	Day 14 (±2 days) after randomization	Day 28 (±3 days) after randomization	Safety FU 28 (±3) days after last dose of acalabrutinib <sup>l,m</sup>	Long-term FU 90 (±7) days after randomization <sup>j,k</sup>	CSP section
Acalabrutinib administration		<b>The first dose of acalabrutinib must be administered within 6 hours of randomization</b> 100 mg bid (q12h) x 10 days (maximum)						<a href="#">6.1</a>
Adverse events	X <sup>l</sup>	X	X	X	X	X <sup>j</sup>		<a href="#">8.6</a>
Concomitant medications	X	X	X	X	X	X <sup>j</sup>		<a href="#">8.2</a>
Survival status				X	X	X <sup>j</sup>	X <sup>j</sup>	<a href="#">4.5</a>

anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface antigen; aPTT = activated partial thromboplastin time; bid = twice daily; CD = cluster of differentiation; FU = follow-up; BNP = brain natriuretic peptide; COVID-19 = coronavirus disease 2019; CSP = Clinical Study Protocol; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; ICF = Informed Consent Form; INR = international normalized ratio; PT = prothrombin time; q12h = every 12 hours; RT-PCR = reverse transcriptase-polymerase chain reaction; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WOCBP = women of childbearing potential.

<sup>a</sup> Pre-dose.

<sup>b</sup> Hematology: complete blood count with differential includes, but not limited to white blood cell count, hemoglobin, platelet count, absolute neutrophil count (ANC) or percentage, red blood cell count, absolute monocyte count or percentage, and absolute lymphocyte count (ALC) or percentage.

<sup>c</sup> Serum or plasma chemistry: albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), magnesium, phosphate, potassium, sodium, total bilirubin, total protein and uric acid.

<sup>d</sup> Hepatitis serology must include HBsAg, anti-HBs, anti-HBc, and HCV antibody. Additional testing information is provided in [Section 6.6.3](#).

<sup>e</sup> COVID-19 infection must be confirmed according to the World Health Organization criteria (including positive nucleic acid test of any specimen [eg, respiratory, blood, urine, stool, or other bodily fluid]) within 4 days prior to randomization. If test has already been documented within 4 days prior to randomization, no need to repeat the testing again.

<sup>f</sup> Serum sample will be used for SARS-CoV-2 quantitative serology assay and other exploratory analysis.

<sup>g</sup> Flow cytometry testing of peripheral blood will include, but is not limited to, CD3+, CD4+, CD8+, CD14+, CD19+, and CD16+/56+ cells.

<sup>h</sup> If a subject is discharged prior to Day 10, he/she needs to visit the site for an assessment 2 to 4 days after discharge. Assessments should match those for Day 10.

<sup>i</sup> Subjects who receive acalabrutinib should have follow up assessments for safety 28 (± 3) days after the last dose of acalabrutinib.

<sup>j</sup> Telemedicine is recommended for capturing adverse events and concomitant medications. Safety laboratory tests can be done at the hospital or a local laboratory provided the results are ultimately captured in the clinical database for the study.

<sup>k</sup> All subjects will be followed for survival for 90 (± 7) days.

<sup>l</sup> After signing ICF, but prior to randomization, only SAEs should be reported (see [Section 8.6.2](#)).

<sup>m</sup> For subjects who receive BSC only (Arm 2), concomitant medication, adverse event, and survival assessments will occur via telemedicine through 28 (± 10) days after randomization.

## 1.2 Synopsis

### Protocol Title:

A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

### Rationale:

Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most COVID-19 cases (~80%) are mild respiratory illnesses. However, some require hospitalization (mostly due to pneumonia) and can progress quickly to severe acute lung injury and acute respiratory distress syndrome (ARDS) ([Huang 2020](#); [Wu 2020](#); [Zhou 2020](#)), which is associated with high mortality. A viral-induced cytokine storm or “hyperimmune response” is hypothesized to be a major pathogenic mechanism of ARDS in these patients through modulation of pulmonary macrophages and dendritic cells ([Channappanavar 2016](#); [Huang 2005](#); [Wong 2004](#); [Yoshikawa 2009](#)) and/or neutrophils ([Herold 2015](#)). Putative inflammatory mediators include interleukin (IL)-1 $\beta$ , IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNF $\alpha$ ), and monocyte chemoattractant protein-1 (MCP-1) ([Chen 2020](#); [Herold 2015](#), [Yoshikawa 2009](#)).

Bruton’s tyrosine kinase (Btk) is a Tec family non-receptor protein kinase, expressed in B cells, myeloid cells, osteoclasts, mast cells and platelets. The function of Btk in signaling pathways activated by the engagement of the B-cell receptor has been well established ([Buggy 2012](#)). Btk is also involved in the following biologic processes: Fc gamma receptor signaling in myeloid cells, mast cell degranulation, osteoclast differentiation, and signaling through Toll-like receptors (TLRs) in macrophages and neutrophils. Btk inhibition is associated with a decrease in proinflammatory cytokines in patients with hematologic malignancies.

Acalabrutinib is a covalent Btk inhibitor with greater selectivity and better physiochemical properties than ibrutinib and other Btk inhibitors currently in development. Acalabrutinib is currently approved in the United States for the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma [Calquence® prescribing information]. Patients with hematologic malignancies treated with acalabrutinib have shown statistically significant decreases in the following cytokines: TNF $\alpha$  (p<0.001), IL-10 (p<0.001), and MCP-1 (p<0.01) ([Byrd 2016](#)) and IL-6 (p<0.05) (data on file). Decreasing these immunomodulating cytokines in patients with COVID-19 may mitigate the pathophysiologic response that leads to the most severe morbidity and mortality associated with viral infection. Thus far, data reporting clinical outcomes for the use of Btk inhibitors for COVID-19 have been encouraging but anecdotal and limited to case series ([Trean 2020](#)).

The purpose of this Phase 2 study is to evaluate the preliminary efficacy and safety of adding acalabrutinib to best supportive care (BSC) for subjects with life-threatening COVID-19 symptoms.

### Objectives and Endpoints:

Primary Objective	Primary Endpoints/Variables
The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19	<p>Proportion of subjects alive and free of respiratory failure at Day 14</p> <p>For the purpose of this study, <b>respiratory failure</b> is defined based on resource utilization of any of the following modalities:</p> <ul style="list-style-type: none"> <li>○ Endotracheal intubation and mechanical ventilation</li> <li>○ Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates &gt;20 L/min with fraction of delivered oxygen <math>\geq 0.5</math>)</li> <li>○ Noninvasive positive pressure ventilation or continuous positive airway pressure</li> <li>○ Extracorporeal membrane oxygenation</li> </ul>
Secondary Efficacy Objective	Secondary Efficacy Endpoints/Variables
To evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19	<ul style="list-style-type: none"> <li>● Proportion of subjects alive and free of respiratory failure (defined above) at Day 28</li> <li>● Percent change from baseline in C-reactive protein (CRP; time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>● Change from baseline in ferritin (time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>● Change from baseline in absolute lymphocyte counts (time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>● All-cause mortality at Day 90</li> <li>● Proportion of subjects alive and discharged from the intensive care unit (ICU) at Days 14 and 28</li> <li>● Time from randomization to first occurrence of respiratory failure or death on study (up to 28 days after randomization) due to any cause</li> <li>● Number of days alive and free of respiratory failure from randomization to 28 days after randomization</li> </ul>

	<ul style="list-style-type: none"> <li>• Number of days with respiratory failure from randomization to 28 days after randomization</li> <li>• Number of days hospitalized from randomization to 28 days after randomization</li> <li>• Number of days in ICU (length of stay) from randomization to 90 days after randomization</li> <li>• Number of days alive outside of hospital from randomization to 28 days after randomization</li> <li>• Number of days alive outside of hospital from randomization to 90 days after randomization</li> <li>• Relative change from baseline in oxygenation index (<math>\text{PaO}_2/\text{FiO}_2</math>) to Day 5</li> </ul>
<b>Safety Objective</b>	<b>Safety Endpoint/Variable</b>
To evaluate the safety of acalabrutinib in subjects with COVID-19 when administered with BSC	Type, frequency, severity, and relationship to study treatment of any treatment-emergent adverse events (TEAEs) or abnormalities of laboratory tests, serious adverse events (SAEs), or adverse events (AEs) leading to discontinuation of study treatment
<b>Pharmacokinetic (PK) Objective</b>	<b>PK Endpoint/Variable</b>
To assess PK of acalabrutinib and its active metabolite in subjects with COVID-19 when administered with BSC	Acalabrutinib maximum observed concentration ( $C_{\text{max}}$ ), time to $C_{\text{max}}$ ( $t_{\text{max}}$ ), half-life ( $t_{1/2}$ ), $\text{AUC}_{0-\text{time}}$ , and its active metabolite, ACP-5862 $C_{\text{max}}$ , and other PK parameters (eg $\text{CL}/F$ or $\text{Vdss}/F$ ) where appropriate
<b>Exploratory Objectives</b>	<b>Exploratory Endpoints/Variables</b>
<ul style="list-style-type: none"> <li>• Evaluate changes in inflammatory cytokines/chemokines associated with COVID-19</li> <li>• SARS-CoV-2 and quantitative serology</li> <li>• Pharmacodynamic effects of acalabrutinib</li> </ul>	<ul style="list-style-type: none"> <li>• Change from baseline in cytokine/chemokines such as <math>\text{INF}\gamma</math>, <math>\text{TNF}\alpha</math>, <math>\text{IL-1}\beta</math>, IL-6, IL-8, IL-10, IL-18, MCP-1, etc</li> <li>• Change from baseline in SARS-CoV-2 levels and serology</li> <li>• Btk occupancy compared to pre-dose</li> <li>• Correlative analysis with treatment effects to determine if any biomarkers can predict response, as well as any relationship to study drug exposure levels</li> </ul>

### Overall Design:

This is a multicenter, randomized, open-label, Phase 2 study that will evaluate acalabrutinib plus BSC versus BSC in subjects with COVID-19 who are hospitalized.

Subjects will be randomly assigned (1:1) to receive one of the following 2 treatments:

- Arm 1: Acalabrutinib 100 mg twice daily (bid) x 10 days + BSC (n=70)
- Arm 2: BSC alone (n=70)

For the purpose of this study, BSC is per discretion of the Investigator and institutional guidelines. However, refer to [Section 5.2](#) and [Section 6.5.3](#) for prohibited or restricted concomitant therapy. Subjects will be randomized based on the following stratification factors, which are considered prognostic factors for poor outcome:

- Age ( $\geq 65$  vs  $< 65$  years)
- Comorbidities (present vs absent). “Present” is defined as having at least 1 of the following comorbidities:
  - Cardiovascular disease, as defined by either heart failure New York Heart Association class  $\geq 2$  or hypertension requiring treatment
  - Diabetes mellitus requiring treatment
  - Chronic obstructive pulmonary disease or asthma requiring treatment
  - Current active solid tumor or hematologic malignancy

Inclusion/exclusion criteria are provided in [Section 5](#). Assessments are provided in [Table 1](#).

#### **Study Period:**

Estimated date of first subject enrolled Q2 2020.

Estimated date of last subject completed is Q3 2020.

#### **Number of Subjects:**

The total number of subjects to be randomized in this study is 140.

#### **Treatments and Treatment Duration:**

Acalabrutinib 100 mg bid will be administered for a maximum of 10 days (treatment beyond 10 days is not permitted). BSC will be administered across all arms per Investigator’s discretion and institutional guidelines. Subjects who have respiratory failure before completing the maximum treatment period will be permitted to continue treatment with acalabrutinib for the maximum treatment period, according to the Investigator’s clinical judgment.

Subjects who can no longer swallow pills, such as those with nasogastric or enteral feeding tubes utilized for mechanical ventilation, will not be eligible to continue acalabrutinib treatment.

Retreatment with acalabrutinib is not allowed.

### **Internal Data Monitoring Committee:**

An internal Data Monitoring Committee (iDMC), independent from the Sponsor's study team, will be established to enable early identification of safety signals in the study, minimize risk to subjects during the study, and make recommendations as to the future conduct of this study in accordance with the iDMC charter (refer to [Section 4.4](#) for details).

### **Statistical Methods:**

In general, continuous data will be summarized using descriptive statistics (number of observations, mean, standard deviation, median, 25th and 75th percentiles, minimum, and maximum). Frequencies and percentages will be used for summarizing categorical (discrete) data.

For subjects randomized to Arms 1 or 2, efficacy will be summarized for the intent-to-treat (ITT) population, which is defined as all subjects who were randomized, to be analyzed according to the arm to which they are randomly assigned, following "intent-to-treat" principle. An estimate of the primary endpoint, the proportion of subjects who are alive and free of respiratory failure at Day 14 and its 95% confidence interval (CI; using Blyth-Still-Casella method) will be calculated for each treatment arm. The Cochran-Mantel-Haenszel  $\chi^2$  test stratified by age ( $\geq 65$  vs  $< 65$  years) and comorbidities (present vs absent) will be used to compare the proportion of subjects who are alive and free of respiratory failure at Day 14 between the two treatment arms. An unstratified analysis will also be performed. Finally, the difference in the proportion of subjects who are alive and free of respiratory failure at Day 14 will also be provided with 95% CIs.


Safety will be summarized for the treated population (Safety population) and will be based on the treatment they actually received. In this study, treatment is either acalabrutinib + BSC or BSC only. If a subject receives at least 1 dose of acalabrutinib, the subject is considered as acalabrutinib-treated, regardless to which arm the subject was randomized. Safety assessments will consist of monitoring and recording AEs, SAEs and AEs leading to discontinuation of study treatment; measurements of protocol-specified hematology, clinical chemistry, and other laboratory variables; measurement of protocol-specified vital signs; and other protocol-specified tests that are deemed critical to the safety evaluation of the study treatment.

Refer to [Section 9](#) for additional details.

## **1.3 Schema**

The general study design is summarised in [Figure 1](#).

**Figure 1 Study Design**



bid = twice per day; BSC = best supportive care (for COVID-19 symptoms); SARS-CoV-2+ = severe acute respiratory syndrome coronavirus 2 positive.

## 2. INTRODUCTION

### 2.1 Background and Study Rationale

Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a retrospective study of 191 patients with COVID-19, sepsis was the most frequently observed complication, followed by respiratory failure, acute respiratory distress syndrome (ARDS), heart failure, and septic shock. While sepsis might be directly caused by SARS-CoV-2 infection, further research is needed to investigate the pathogenesis of COVID-19 illness. Most COVID-19 cases (~80%) are mild respiratory illnesses. 5% to 15% of these respiratory illnesses require hospitalization (mostly due to pneumonia) and can progress quickly to severe acute lung injury and ARDS (Huang 2020; Wu 2020; Zhou 2020), which is associated with high mortality.

Normally, human coronaviruses are detected and cleared by the immune system, but a subset of patients experience increased severity of symptoms (Channappanavar 2017; Zhou 2020). These symptoms have been associated with the loss of control of the virally induced immune response (Li 2020). In these cases, the inflammatory response is hypothesized to be a major pathogenic mechanism of ARDS through modulation of pulmonary macrophages and dendritic cells (Channappanavar 2016; Huang 2005; Wong 2004; Yoshikawa 2009) and/or neutrophils (Herold 2015). Putative inflammatory mediators include interleukin (IL)-1 $\beta$ , IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNF $\alpha$ ), and monocyte chemoattractant protein-1 (MCP-1) (Chen 2020; Herold 2015, Yoshikawa 2009). During the acute phase of coronavirus infection, T cells are the critical mediators of clearance of infection, while B cells generate a protective humoral response (Zhao 2014; Zhao 2009). Generation of antibodies against coronaviruses is not always protective. In a mouse model, an anti-spike immunoglobulins (specific to SARS-COV) could skew the inflammation-resolving response which lead to severe acute lung injury in mice (Liu 2019).

Bruton's tyrosine kinase (Btk) is a Tec family nonreceptor protein kinase, expressed in B cells, myeloid cells, osteoclasts, mast cells, and platelets. The function of Btk in signaling pathways activated by the engagement of the B-cell receptor has been well established (Buggy 2012). Btk is also involved in the following biologic processes: Fc gamma receptor signaling in myeloid cells, mast cell degranulation, and signaling through Toll-like receptors (TLRs) in macrophages and neutrophils. Specifically, Btk is required for TLR 7/8 signaling, which recognize single strand RNA viruses such as coronaviruses, signal through Btk in macrophages (Page 2018).

Recently, Btk inhibition has shown to rescue mice from lethal influenza A-virus induced acute lung injury by significantly decreasing lung inflammation and macrophage/monocyte mediated cytokines/chemokines (TNF $\alpha$ , IL-1 $\beta$ , IL-6, MCP-1, etc) in the lung homogenates.

These results suggest that Btk inhibition may represent a new immunomodulatory treatment for virally induced lung damage driven by excessive inflammation (Florence 2018). Additionally, in a murine model of sepsis, acalabrutinib has shown to ameliorate the cardiac dysfunction by suppressing pro-inflammatory cytokines/chemokines associated with sepsis (O’Riordan 2019). Patients with hematologic malignancies treated with acalabrutinib (Calquence®) have shown significant reduction of several cytokines/chemokines including pro-inflammatory markers such as: TNF $\alpha$  (p<0.001), IL-10 (p<0.001), MCP-1 (p<0.01), MIP-1beta (p<0.001), MIP-1 alpha (p<0.001), IL-16 (p<0.001), TARC (p<0.001), CXCL13 (p<0.001), Granzyme A (p<0.001) (Byrd 2016; Covey 2017), and IL-6 (p<0.05) (data on file). Several of these cytokines/chemokines have been shown to be associated with more severe illness in COVID-19 patients. We hypothesize that acalabrutinib treatment will inhibit cells that produce pro-inflammatory cytokines/chemokines, will lead to reduced inflammation of the lungs in patients with COVID-19, and mitigate the pathophysiologic response that leads to the most severe morbidity and mortality associated with viral infection. Thus far, data reporting clinical outcomes for the use of Btk inhibitors for COVID-19 have been encouraging but anecdotal and limited to case series (Treon 2020).

Together, strong scientific evidence justifies a clinical trial in this patient population. The purpose of this Phase 2 study is to evaluate the preliminary efficacy and safety of adding acalabrutinib to best supportive care (BSC) for subjects hospitalized due to COVID-19 symptoms.

## 2.2 Benefit/Risk Assessment

The lack of established treatments and vaccines for the novel SARS-CoV-2 virus has driven major medical centers to an unprecedented overload, which has undoubtedly contributed to the mortality observed with this disease. While vaccines and antiviral therapies are urgently needed, drugs that can address the pathophysiology of the disease to decrease the morbidity and mortality and reduce hospital admissions and intensive care unit (ICU) use are also needed without delay.

Btk inhibition may serve as an important addition to the COVID-19 armamentarium by reducing the viral-induced hyperimmune response, which leads to lung destruction. Acalabrutinib is currently approved in the United States for the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. As of 30Oct2019, acalabrutinib has been administered to over 3300 participants in clinical studies, including subjects with hematologic malignancies, solid tumors, or rheumatoid arthritis, and participants who are healthy subjects or those with mild to moderate hepatic impairment. No serious adverse events (SAEs) have been reported in the hepatic impairment trial or in the healthy volunteer trials. Some subjects with chronic lymphocytic leukemia have been receiving acalabrutinib therapy for more than 5 years. Acalabrutinib has been administered alone and in combination with other kinase inhibitors, anti-CD20 antibodies,

chemoimmunotherapy (eg, bendamustine/rituximab), and an anti-programmed cell death 1 (PD-1) receptor antibody. No dose-limiting toxicities (DLTs) have been identified for acalabrutinib monotherapy or when administered in combination with the aforementioned agents. Current clinical safety data supports combining acalabrutinib with other agents.

Refer to the acalabrutinib Investigator's Brochure for the most up to date safety and efficacy information. Identified risks for acalabrutinib are summarized in [Section 6.6](#) and are based on events observed in subjects with cancer who have been on long-term treatment with acalabrutinib 100 mg twice daily (bid).

Based on the safety profile of acalabrutinib to date, no overt toxicities have been identified that would preclude acute treatment for subjects with moderate to severe COVID-19 symptoms.

Precautionary safety measures, in addition to regular monitoring of safety by an internal Data Monitoring Committee (iDMC) and the Sponsor, are included in the study design to enable early identification of safety signals in the study and minimize the risk to subjects.

### 3. OBJECTIVES AND ENDPOINTS

**Table 2 Protocol Objectives and Endpoints**

Primary Objective	Primary Endpoints/Variables
The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19	<p>Proportion of subjects alive and free of respiratory failure at Day 14</p> <p>For the purpose of this study, <b>respiratory failure</b>, is defined based on resource utilization of any of the following modalities:</p> <ul style="list-style-type: none"><li>(a) Endotracheal intubation and mechanical ventilation</li><li>(b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates &gt;20 L/min with fraction of delivered oxygen <math>\geq 0.5</math>)</li><li>(c) Noninvasive positive pressure ventilation or continuous positive airway pressure</li><li>(d) Extracorporeal membrane oxygenation</li></ul>

Secondary Efficacy Objective	Secondary Efficacy Endpoints/Variables:
To evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19	<ul style="list-style-type: none"> <li>• Proportion of subjects alive and free of respiratory failure (as defined above) at Day 28</li> <li>• Percent change from baseline in CRP (time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>• Change from baseline in ferritin (time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>• Change from baseline in absolute lymphocyte counts (time frame: baseline, Days 3, 5, 7, 10, 14, 28)</li> <li>• All-cause mortality at Day 90</li> <li>• Proportion of subjects alive and discharged from the ICU at Days 14 and 28</li> <li>• Time from randomization to first occurrence of respiratory failure or death on study (up to 28 days after randomization) due to any cause</li> <li>• Number of days alive and free of respiratory failure from randomization to 28 days after randomization</li> <li>• Number of days with respiratory failure from randomization to 28 days after randomization</li> <li>• Number of days hospitalized from randomization to 28 days after randomization</li> <li>• Number of days in ICU (length of stay) from randomization to 90 days after randomization</li> <li>• Number of days alive outside of hospital from randomization to 28 days after randomization</li> <li>• Number of days alive outside of hospital from randomization to 90 days after randomization</li> <li>• Relative change from baseline in oxygenation index (<math>\text{PaO}_2/\text{FiO}_2</math>) to Day 5</li> </ul>
Safety Objective	Safety Endpoint/Variable
To evaluate the safety of acalabrutinib in subjects with COVID-19 when administered with BSC	Type, frequency, severity, and relationship to study treatment of any TEAEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study treatment
PK Objective	PK Endpoint/Variable
To assess PK of acalabrutinib and its active metabolite in subjects with COVID-19 when administered with BSC	Acalabrutinib $C_{\max}$ , $t_{\max}$ , $t_{1/2}$ , $\text{AUC}_{0-\text{time}}$ , and its active metabolite, ACP-5862 $C_{\max}$ , and other PK parameters (eg $\text{CL}/F$ or $\text{Vd}_{\text{ss}}/F$ ) where appropriate

Exploratory Objectives	Exploratory Endpoints/Variables
<ul style="list-style-type: none"> <li>Evaluate changes in inflammatory cytokines/chemokines associated with COVID-19</li> <li>SARS-CoV-2 and quantitative serology</li> <li>Pharmacodynamic effects of acalabrutinib</li> </ul>	<ul style="list-style-type: none"> <li>Change from baseline in cytokines/chemokines such as <math>\text{INF}\gamma</math>, <math>\text{TNF}\alpha</math>, <math>\text{IL-1}\beta</math>, IL-6, IL-8, IL-10, IL-18, MCP-1, etc</li> <li>Change from baseline in SARS-CoV-2 levels and serology</li> <li>Btk occupancy compared to pre-dose</li> <li>Correlative analysis with treatment effects to determine if any biomarkers can predict response, as well as any relationship to study drug exposure levels</li> </ul>

AE = adverse event; AUC = area under the concentration-time curve; BSC = best supportive care; Btk = Bruton's tyrosine kinase; CL/F = apparent clearance;  $C_{\max}$  = maximum observed concentration; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein;  $\text{FiO}_2$  = fraction of inspired oxygen; ICU = intensive care unit; IL = interleukin;  $\text{INF}\gamma$  = interferon gamma; MCP-1 = monocyte chemoattractant protein-1;  $\text{PaO}_2$  = partial pressure of oxygen; PK = pharmacokinetics; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2;  $t_{1/2}$  = half-life; TEAE = treatment-emergent adverse event;  $t_{\max}$  = time to maximum observed concentration;  $\text{TNF}\alpha$  = tumor necrosis factor alpha;  $\text{Vd}_{\text{ss}}/\text{F}$  = apparent volume of distribution at steady-state.

## 4. STUDY DESIGN

### 4.1 Overall Design

This is a multicenter, randomized, open-label, Phase 2 study that will evaluate acalabrutinib plus BSC versus BSC in subjects with COVID-19 who are hospitalized.

Subjects will be randomly assigned (1:1) to receive one of the following 2 treatments:

- Arm 1: Acalabrutinib 100 mg twice daily (bid) x 10 days + BSC (n=70)
- Arm 2: BSC alone (n=70)

For the purpose of this study, BSC is per discretion of the Investigator and institutional guidelines. However, refer to [Section 5.2](#) and [Section 6.5.3](#) for prohibited or restricted concomitant therapy. Subjects will be randomized based on the following stratification factors, which are considered prognostic factors for poor outcome:

- Age ( $\geq 65$  vs  $< 65$  years)
- Comorbidities (present vs absent). "Present" is defined as having at least 1 of the following comorbidities:
  - Cardiovascular disease, as defined by either heart failure New York Heart Association (NYHA) class  $\geq 2$  or hypertension requiring treatment
  - Diabetes mellitus requiring treatment
  - Chronic obstructive pulmonary disease or asthma requiring treatment

- Current active solid tumor or hematologic malignancy

Inclusion/exclusion criteria are provided in [Section 5](#). Assessments are provided in [Table 1](#).

## 4.2 Scientific Rationale for Study Design

The immune system is required to clear viral infections and generate protective immunity from viral pathogens like SARS-CoV-2. There is significant evidence that in patients with severe respiratory problems, the immune system and inflammation contribute to the severity of the disease. Macrophages and neutrophils are key to producing cytokines driving this inflammation. The hypothesis being evaluated in this trial is whether Btk inhibition of the viral-induced macrophage and neutrophil immune response can decrease inflammation and reduce respiratory failure or death. Given the various covariates that contribute to these outcomes (eg, lack of consensus on standard of care, actively changing local treatment practices, and patients' comorbid conditions), a single-arm study will likely not be informative as data from historical controls are changing almost daily. Hence, this will be a randomized study. Subjects who are hospitalized for COVID-19 disease and meet the eligibility criteria will be randomized 1:1 to receive acalabrutinib plus BSC (n=70) versus BSC (n=70).

Stratification by age and comorbidities will be applied to randomization as these are expected to be important covariates.

## 4.3 Justification for Dose

Acalabrutinib 100 mg bid has been evaluated in various indications (ie, B-cell malignancies and solid tumours) alone and in combination with anti-CD20 antibodies, chemotherapy, a phosphatidylinositol-3-kinase (PI3K) inhibitor, and an anti-PD-1 antibody. No DLTs have been identified for acalabrutinib alone or when given in combination with these agents. For all of these indications, acalabrutinib was administered daily until disease progression; some subjects have been receiving acalabrutinib for > 5 years. The long-term safety experience of chronic administration of acalabrutinib 100 mg bid monotherapy and in combination with other agents, supports the proposed dosage of acalabrutinib is 100 mg bid for acute treatment. In addition, correlative studies—in subjects with chronic lymphocytic leukemia treated with acalabrutinib 200 mg once daily (qd) or 100 mg bid—show bid dosing maintained higher Btk occupancy and achieved more potent NF-kappaB pathway inhibition compared with qd dosing ([Sun 2020](#)). Activation of NF-kappaB occurs in the lungs of patients with ARDS and may contribute to the increased expression of proinflammatory mediators ([Moine 2000](#)). Therefore, 100 mg bid dosing is proposed for this study to ensure maximum target engagement.

## 4.4 Internal DMC

This study will have an iDMC. Details of the roles and responsibilities of the iDMC are provided in a charter separate from the protocol. The iDMC will be responsible for reviewing

the safety periodically. The first safety review will occur approximately 28 days after the first 30 subjects (data cutoff) are randomized into the study. The second safety review will occur approximately 28 days after the first 80 subjects (data cutoff) are randomized into the study.

In addition, the iDMC will review all fatal events on an ongoing basis. Further details will be provided in a separate iDMC charter.

## 4.5 End of Study Definition

The end of study is defined as the last expected visit/contact of the last subject undergoing the study.

A subject is considered to have completed the study when he/she has completed his/her last scheduled procedure shown in the Schedule of Activities (SoA; [Section 1.1](#)). All randomized subjects will be followed for survival through 90 ( $\pm$  7) days after randomization.

All subjects who discontinue the investigational study treatment for any reason other than withdrawal of consent, loss to follow-up, or death will have a safety follow up assessment 28 ( $\pm$  3) days after the last dose of acalabrutinib as outlined in [Section 1.1](#).

The study may be stopped if, in the judgment of the Sponsor, study subjects are placed at undue risk because of clinically significant findings.

See [Appendix A 6](#) for guidelines for the dissemination of study results.

## 5. STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

Each subject should meet all the inclusion criteria and none of the exclusion criteria for this study to be assigned to a study intervention. Under no circumstances can there be exceptions to this rule. Subjects who do not meet the entry requirements are screen failures, refer to [Section 5.3](#).

### 5.1 Inclusion Criteria

Subjects are eligible to be included in the study only if **all** of the criteria below apply.

1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

2. Men and women  $\geq 18$  years of age at the time of signing the Informed Consent Form (ICF).
3. SARS-CoV-2 confirmed per World Health Organization (WHO) criteria (including positive nucleic acid test of any specimen [eg, respiratory, blood, urine, stool, or other bodily fluid]) within 4 days of randomization.
4. COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation  $< 94\%$  on room air or requires supplemental oxygen.
5. Able to swallow pills.
6. Willing to follow contraception guidelines (refer to [Appendix F](#)).

## 5.2 Exclusion Criteria

Subjects are excluded from the study if **any** of the criteria below apply.

### COVID-19 Related Medical Conditions

1. Respiratory failure at the time of screening (see [Section 3](#) for definition of respiratory failure) due to COVID-19 pneumonia.
2. Known medical resuscitation within 14 days of randomization.
3. Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the subject's safe participation in and completion of the study.
4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARSCoV2).
5. In the opinion of the Investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.

### Medical Conditions

6. Not expected to survive 28 days given their preexisting, uncorrectable medical condition, for example, subjects with, or suspected to have, the following conditions: multiorgan failure, poorly controlled neoplasms; endstage cardiac disease; cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within past 30 days; endstage lung disease; endstage liver disease; or human immunodeficiency virus/acquired immunodeficiency syndrome with known endstage process.
7. Pregnant or breast feeding.
8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin  $\geq 3\times$  upper limit of normal (ULN) and/or severe hepatic impairment (Child-Pugh class C; see [Appendix G](#)) detected within 24 hours at screening (per local laboratory).
9. Absolute neutrophil count (ANC)  $< 500/\mu\text{L}$  at screening (per local laboratory).
10. Platelet count  $< 50,000/\mu\text{L}$  at screening (per local laboratory).

11. Estimated creatinine clearance of  $<30$  mL/min calculated using the Cockcroft-Gault formula  $[(140 \times \text{age}) \times \text{mass (kg)}] / (72 \times \text{creatinine mg/dL})$  multiply by 0.85 if female].
12. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4).  
Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
13. History of chronic hypercarbia, respiratory failure in past 6 months, or use of home oxygen in the setting of severe chronic respiratory disease.
14. Quadriplegia.
15. History of primary immunodeficiency, tuberculosis, progressive multifocal leukoencephalopathy (PML), aspergillus or other invasive mold/fungal infection, or received organ or bone marrow transplantation within 6 months of randomization.
16. Known active hepatitis B or C infection requiring therapy.

#### **Prior/Concomitant Therapy**

17. Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 14 days before first dose of study drug) or inducer (within 7 days before first dose of study drug).
18. Requires treatment with proton-pump inhibitors (PPIs; eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving PPIs who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study.
19. Received oral antirejection or immunomodulatory drugs (eg, anti-cytokines, Btk inhibitors, JAK inhibitors, PI3K inhibitors) within 30 days before randomization.
20. Active participation in other drug clinical trials or received treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization/enrollment.  
Exception: Subjects may receive COVID-specific antiviral drugs (eg, remdesivir, hydroxychloroquine).
21. Subjects at randomization who require inhaled corticosteroids or maintenance doses of more than 7.5 mg of prednisone or equivalent per day.
22. Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of acalabrutinib.
23. History of hypersensitivity (ie, allergic response) to active or inactive excipients of acalabrutinib or other Btk inhibitors.
24. Known cytoreductive chemotherapy treatment within 14 days of randomization.
25. Major surgery (as defined by the Investigator) within 4 weeks prior to randomization or still recovering from prior surgery.

### 5.3 Screen Failures

Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently randomized. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE unrelated to the disease under investigation.

Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened. Rescreened subjects should be assigned the same subject number as for the initial screening.

## 6. STUDY TREATMENTS

Study treatment is defined as any investigational product(s) (including marketed product comparator and placebo) or medical device(s) intended to be administered to a study subject according to the study protocol. Study treatment in this study refers to acalabrutinib.

### 6.1 Treatments Administered

Acalabrutinib treatment should begin on Day 1. Subjects will take acalabrutinib 100 mg capsules bid by mouth. Capsules will be taken with 8 ounces (approximately 240 mL) of water. The capsules should be swallowed intact and subjects should not attempt to open capsules or dissolve them in water. Acalabrutinib can be taken with or without food.

Doses should be scheduled approximately 12 hours apart. It is recommended that acalabrutinib be taken as close to the scheduled time as possible (within  $\pm 1$  hour). However, if a dose is missed, it can be taken up to 3 hours after the scheduled time, with a return to the normal schedule upon the following dose for a maximum of 10 days.

**Acalabrutinib treatment must be administered within 6 hours of randomization.**

Subjects who have respiratory failure before completing the maximum treatment period will be permitted to continue treatment with acalabrutinib for the maximum treatment period, according to the Investigator's clinical judgment.

Subjects who can no longer swallow pills will not be eligible to continue acalabrutinib treatment.

Retreatment with acalabrutinib is not allowed.

If vomiting occurs after taking acalabrutinib, the subject should not retake acalabrutinib until the next scheduled dose.

Subjects who are discharged from the hospital before they have completed 10 days of acalabrutinib therapy will be required to complete the remaining dosing at home. They should adhere to their established dosing schedule. These subjects must complete a drug dosing diary to be faxed or mailed back to the study site.

Drug-drug interactions may occur with some of the drugs being used as BSC (eg, drugs that are moderate inhibitor of CYP3A), and dosing of acalabrutinib may need to be adjusted. Please refer to [Section 6.5.4](#) for detailed information and guidance.

## **6.2 Acalabrutinib Preparation/Handling/Storage/Accountability**

Acalabrutinib should be stored according to the instructions on the label affixed to the package of the drug product.

If a drug shipment arrives damaged or if there are any other drug complaints, a Product Complaint Form should be completed and emailed to the Sponsor or the Sponsor's representative. Refer to the pharmacy manual and the Investigator's Brochure for additional information regarding the drug product to be used in this study.

The Investigator or designee (eg, unblinded pharmacist) must confirm appropriate temperature conditions have been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment.

Only subjects enrolled in the study may receive study treatment and only authorized site staff may supply or administer study treatment. All study treatments must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and authorized site staff.

The Investigator, institution, or the head of the medical institution (where applicable) is responsible for study treatment accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

Further guidance and information for the final disposition of unused study treatment are provided in the Clinical Study Agreement.

## **6.3 Measures to Minimise Bias: Randomisation and Blinding**

Given the urgent nature of the COVID-19 pandemic, this will be an open-label study. However, the study is randomized and include stratification factors as outlined in [Section 4.1](#).

### 6.3.1 Subject Enrollment and Randomization

All eligible subjects will be centrally randomized using an interactive response technology (IRT) that will assign the subjects to either acalabrutinib plus BSC versus BSC, stratified by the stratification factors defined in [Section 4.1](#). Before the study is initiated, log-in information and directions for the IRT will be provided to each site.

Investigators should keep a record (ie, the subject screening log) of subjects who entered screening.

At screening, the Investigators or suitably trained delegate will:

- Obtain informed consent before any study specific procedures are performed.
- Obtain a unique 7-digit enrollment number (E-code), through the IRT the following format (ECCNNXXX: CC being the country code, NN being the center number, and XXX being the subject enrollment code at the center). This number is the subject's unique identifier and is used to identify the subject on the electronic case report forms (eCRFs).
- Determine subject eligibility (see [Section 5.1](#) and [Section 5.2](#)).

At randomization, once the subject is confirmed to be eligible, the Investigator or suitably trained delegate will:

- Log the E-code and stratification factors (age  $\geq 65$  vs  $< 65$  years] and comorbidities [present vs absent]) in the IRT system and the system will sequentially randomize the eligible subject to 1 of the 2 treatment arms.
- If the subject is ineligible and not randomized, the IRT should be contacted to terminate the subject in the system.
- Subjects will begin treatment on Day 1. Treatment should start no more than 6 hours after being randomized. Subjects must not be randomized and treated unless all eligibility criteria have been met.

If a subject withdraws from participation in the study, then his/her enrollment/randomization code cannot be reused. A withdrawn subject will not be replaced.

#### 6.3.1.1 Procedures for Handling Incorrectly Enrolled or Randomized Subjects

Subjects who fail to meet the eligibility criteria should not, under any circumstances, be enrolled or receive study medication. There can be no exceptions to this rule. Subjects who are enrolled, but subsequently found not to meet all the eligibility criteria must not be randomized or initiated on treatment and must be withdrawn from the study.

Where a subject does not meet all the eligibility criteria but is randomized in error, or incorrectly started on treatment, the Investigator should inform the study physician immediately, and a discussion should occur between the study physician and the Investigator

regarding whether to continue or discontinue the subject from treatment. The study physician must ensure all decisions are appropriately documented and that the potential benefit:risk profile remains positive for the subject.

### **6.3.1.2 Methods for Assigning Treatment Groups**

The actual treatment assigned to subjects will be determined by the randomization scheme in the IRT. A stratified permuted block randomization scheme will be used, with the stratification factors defined in [Section 4.1](#). The randomization scheme will be produced by a computer software program that incorporates a standard procedure for generating randomization numbers.

Subjects will be identified to the IRT per country regulations. Randomization codes will be assigned strictly sequentially, within each stratum, as subjects become eligible for randomization.

### **6.3.1.3 Methods for Ensuring Blinding**

This is an open-label study for the personnel at study sites. Specific treatment to be taken by a subject will be assigned using an IRT. The site will contact the IRT prior to the start of study treatment administration for each subject. The site will record the treatment assignment on the applicable case report form, if required. To maintain the integrity of the study, the Sponsor's personnel directly involved in the study conduct will, under no circumstances, view data aggregated by treatment arm during the course of the study.

## **6.4 Treatment Compliance**

The study treatment should only be used as directed in this protocol. Details of treatment with the study treatment, including change from the dosing schedule, dose interruptions, dose reductions, and dose discontinuations, should be recorded in the eCRF. The investigational product will not be distributed to the study site until the contract is concluded between the study site and the Sponsor. The Investigator or designee is responsible for managing the investigational product from time of receipt by the study site until the destruction of all unused investigational product at that site. The Investigator(s) is responsible for ensuring that all unused investigational product is returned to the site by the subject(s).

## **6.5 Concomitant Therapy**

### **6.5.1 Premedications**

No specific premedications or supporting medications are required in conjunction with acalabrutinib administration.

### 6.5.2 Permitted Concomitant Therapy

BSC for COVID-19 (per Investigator discretion and institutional guidelines) is required for all subjects on this protocol except as listed in [Section 5.2](#) and [Section 6.5.3](#).

### 6.5.3 Prohibited or Restricted Concomitant Therapy

#### 6.5.3.1 Medications Prohibited for Subjects Treated with Acalabrutinib

The medications below are prohibited for subjects treated with acalabrutinib.

**Anticoagulants:** Warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) are prohibited.

**Strong CYP3A inhibitors or inducers:** Drug-drug interactions may occur with some of the drugs being used as BSC (eg, drugs that are strong inducers or strong inhibitors of CYP3A). The concomitant use of strong inhibitors of CYP3A (see [Appendix E](#)) should be avoided. If a subject requires a strong CYP3A inhibitor while on treatment with acalabrutinib, discontinue acalabrutinib treatment. Conversely, concomitant administration of a strong inducer of CYP3A has the potential to decrease exposure of acalabrutinib and could reduce efficacy. Therefore, the concomitant use of strong CYP3A inducers should be avoided. If a subject requires a strong CYP3A inducer while on treatment with acalabrutinib, discontinue acalabrutinib. For additional information on drugs with potential drug-drug interactions, refer to [Section 6.5.4](#).

**Proton-pump inhibitors:** The effect of agents that reduce gastric acidity (antacids or PPIs) on acalabrutinib absorption was evaluated in a healthy volunteer study (ACE-HV-004). Results from this study indicate that subjects should avoid the use of calcium carbonate-containing drugs or supplements for a period of at least 2 hours before and at least 2 hours after taking acalabrutinib. Use of omeprazole, esomeprazole, lansoprazole or any other proton-pump inhibitors while taking acalabrutinib is not recommended due to a potential decrease in study drug exposure. Although the effect of H2-receptor antagonists (such as famotidine or ranitidine) on acalabrutinib absorption has not been evaluated, if treatment with an H2-receptor antagonist is required, the H2-receptor antagonist should be taken approximately 2 hours after an acalabrutinib dose. Refer to [Appendix E](#) for a list of PPIs.

#### 6.5.3.2 Medications Prohibited for All Randomized Subjects

The medications below are prohibited for all randomized subjects through Day 14.

**Steroids:** Active systemic corticosteroids exceeding 7.5 mg/day and active inhaled corticosteroids to treat COVID-19 disease symptoms are prohibited for all subjects. Subjects on stable systemic corticosteroids at physiologic doses not exceeding 7.5 mg/day of prednisone or equivalent is allowed. Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication) is also allowed.

**Immunomodulatory drugs:** Immunomodulatory drugs (eg, anti-cytokines, Btk inhibitors, JAK inhibitors, PI3K) are prohibited for all subjects in the study.

Refer to [Section 5.2](#) for additional restrictions on concomitant therapy.

#### 6.5.4 Acalabrutinib Drug-Drug Interaction Guidance in the Presence of Life-threatening COVID-19 Infection

Drug-drug interaction recommendations provided for acalabrutinib in this protocol are made with respect to the presence of life-threatening COVID-19 infection and ability to achieve pharmacodynamic Btk receptor occupancy steady-state in target B-cell and monocytic populations. Therefore, the Sponsor recommends that all eligible subjects with COVID-19 begin dosing with acalabrutinib 100 mg bid. The duration of acalabrutinib therapy will be limited to 10 days. [Table 3](#) provides moderate CYP3A inhibitors and acid reducing agent guidance for subjects with COVID-19. Refer to [Appendix E](#) for a list of common CYP3A inhibitors/inducers and gastric acid reducing medicines.

**Table 3 Acalabrutinib Use with Moderate CYP3A Inhibitors and Gastric Acid Reducing Agents**

	Co-administered Medicines	Recommended Acalabrutinib Use
<b>CYP3A Inhibitor</b>	Moderate CYP3A inhibitor	Monitor subjects closely for adverse reactions if taking moderate CYP3A inhibitors. For subjects who experience an intolerable adverse event (ie, Grade 3-4) attributed to acalabrutinib therapy, reduce the dose to 100 mg once daily.
<b>Gastric Acid Reducing Medicines</b>	H <sub>2</sub> -receptor antagonists	Take acalabrutinib 2 hours before taking a H <sub>2</sub> -receptor antagonist.
	Antacids	Separate dosing by at least 2 hours.

##### 6.5.4.1 Active Substances That May Increase Acalabrutinib Plasma Concentrations CYP3A Inhibitor

Co-administration with a strong CYP3A inhibitor (200 mg itraconazole qd for 5 days) increased acalabrutinib maximum observed concentration ( $C_{max}$ ) and area under the concentration-time curve (AUC) by 3.7- and 5.1-fold in healthy subjects (N=17), respectively.

Consider alternative therapies that do not strongly inhibit CYP3A activity. In subjects requiring strong CYP3A inhibitors (eg, ketoconazole, conivaptan, clarithromycin, indinavir,

itraconazole, ritonavir, telaprevir, posaconazole, voriconazole), discontinue acalabrutinib treatment.

#### **6.5.4.2 Active Substances That May Decrease Acalabrutinib Plasma Concentrations**

##### **CYP3A Inducers**

Co-administration of a strong CYP3A inducer (600 mg rifampin qd for 9 days) decreased acalabrutinib  $C_{max}$  and AUC by 68% and 77% in healthy subjects (N=24), respectively.

Consider alternative therapies to strong inducers of CYP3A activity (eg, phenytoin, rifampin, carbamazepine). Avoid St. John's wort which may unpredictably decrease acalabrutinib plasma concentrations. If these inducers cannot be avoided, discontinue acalabrutinib treatment.

##### **Gastric Acid Reducing Medications**

Acalabrutinib solubility decreases with increasing pH. Co-administration of acalabrutinib with an antacid (1 g calcium carbonate) decreased acalabrutinib AUC by 53% in healthy subjects. Co-administration with a PPI (40 mg omeprazole for 5 days), decreased acalabrutinib AUC by 43%.

If treatment with an acid reducing agent is required, consider using an antacid (eg, calcium carbonate), or an H2-receptor antagonist (eg, ranitidine or famotidine). For use with antacids, separate dosing by at least 2 hours. For H2-receptor antagonists, take acalabrutinib 2 hours before taking the H2-receptor antagonist.

Due to the long-lasting effect of PPIs, separation of doses with PPIs may not eliminate the interaction with acalabrutinib. In subjects requiring treatment with PPIs (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole), discontinue acalabrutinib treatment.

Dose modification of acalabrutinib is not necessary when co-administered with gastric acid reducing medications.

#### **6.6 Risks Associated with Acalabrutinib**

The following summarizes the experience with chronic administration of acalabrutinib in hematologic cancer studies. For more detailed information on treatment-emergent adverse events (TEAEs), refer to the acalabrutinib Investigator's Brochure. Full details regarding the clinical safety of acalabrutinib are presented in Sections 5 and 6 of the acalabrutinib Investigator's Brochure.

### **6.6.1 Hemorrhage**

Bleeding events, some fatal, including central nervous system, respiratory, and gastrointestinal hemorrhage, have been reported in subjects treated with acalabrutinib.

Subjects receiving antiplatelet or anticoagulant therapies may be at increased risk of hemorrhage and should be monitored for signs of bleeding.

Subjects with hemorrhage should be managed per institutional guidelines or as clinically indicated.

### **6.6.2 Infections**

Serious infections, including fatal events, have been reported in subjects treated with acalabrutinib (eg, aspergillosis). Subjects should be monitored for signs and symptoms of infection and treated as medically appropriate. Consultation with the coordinating Investigators or the Medical Monitor is recommended for cases of infection with invasive fungi including aspergillosis.

### **6.6.3 Hepatitis B Reactivation**

Cases of hepatitis B virus (HBV) reactivation have been reported in patients treated with acalabrutinib for an extended period of time with 1 case resulting in liver failure and death. Subjects who are anti-HBc positive or have a known history of HBV infection may be monitored monthly with a quantitative polymerase chain reaction (PCR) test for HBV DNA, when clinically indicated. Any subject with a rising viral load (above lower limit of detection) should discontinue study treatment and have antiviral therapy instituted and a consultation with a physician with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming acalabrutinib in subjects who develop HBV reactivation.

### **6.6.4 Progressive Multifocal Leukoencephalopathy**

Cases of PML have been reported in subjects treated with acalabrutinib for an extended period of time. Signs and symptoms of PML may include cognitive and behavioral changes, language disturbances, visual disturbances, sensory deficits, weakness, and coordination and gait difficulties. If PML is suspected, hold further treatment with acalabrutinib until PML is excluded. If PML is confirmed, permanently discontinue acalabrutinib (see [Section 6.7](#)).

### **6.6.5 Cytopenias**

Grade 3 or 4 events of cytopenias, including neutropenia, anemia, and thrombocytopenia have occurred in subjects treated with acalabrutinib. Monitor blood counts as specified in the SoA and as medically appropriate. Please refer to [Section 6.7](#) for study drug modification guidance. Subjects with cytopenias should be managed according to institutional guidelines or as clinically indicated.

### 6.6.6 Second Primary Malignancies

Second primary malignancies, including non-skin carcinomas solid tumors and skin cancers, have been reported in subjects with B-cell malignancies treated with acalabrutinib. The most frequent second primary malignancy was skin cancer (squamous basal cell carcinoma of the skin). Subjects should be monitored for signs and symptoms of malignancy. Subjects who develop a malignancy should be managed according to institutional guidelines with diagnostic evaluations or as clinically indicated, and it may be necessary for subjects to permanently discontinue study treatment. Continuation of acalabrutinib treatment should be discussed with the Medical Monitor

### 6.6.7 Atrial Fibrillation

Monitor for symptoms of atrial fibrillation and atrial flutter (eg, palpitations, dizziness, syncope, chest pain, dyspnea), and obtain an electrocardiogram (ECG) as clinically indicated. Subjects with atrial fibrillation should be managed per institutional guidelines with supportive care and diagnostic evaluations or as clinically indicated.

### 6.6.8 Reference Safety Information

See the Reference Safety Information in the acalabrutinib Investigator's Brochure for assessment of expectedness of serious adverse reactions.

## 6.7 Dose Modification and Toxicity Management

In general, if a subject experiences a Grade 1 or Grade 2 AE, no dose modification is required. Acalabrutinib therapy should be modified for the following AEs:

Event	Acalabrutinib Dose Modification
Grade 4 neutrophil count decrease (ANC < 500/ $\mu$ L)	<ul style="list-style-type: none"><li>Hold acalabrutinib and introduce G-CSF (continue to monitor ANC)</li><li>Acalabrutinib should only be resumed once neutropenia has resolved to Grade 1 or baseline. If this has not occurred within 3 days of AE onset, discontinue acalabrutinib</li></ul>
Presence of significant bleeding with or without thrombocytopenia	Discontinue acalabrutinib
Grade 4 platelet count decreases if it does not improve to Grade $\leq 2$ with platelet transfusion	Discontinue acalabrutinib
Grade 3 or 4 nausea, vomiting, or diarrhea, if persistent despite optimal antiemetic and/or antidiarrheal therapy	Discontinue acalabrutinib
Any other unmanageable Grade 3 or Grade 4 toxicity	Discontinue acalabrutinib

Event	Acalabrutinib Dose Modification
PML	<ul style="list-style-type: none"><li>• If PML is suspected, hold acalabrutinib until diagnostic evaluation is complete</li><li>• If PML is confirmed, discontinue acalabrutinib</li></ul>

AE = adverse event; ANC = absolute neutrophil count; G-CSF = granulocyte colony-stimulating factor; PML = progressive multifocal leukoencephalopathy.

Clinical judgment should be used to determine appropriate management of the subject during any AE.

Acalabrutinib may be held for a maximum of 3 consecutive days from expected dose due to toxicity. Any other clinically important events where dose delays may be considered appropriate by the Investigator, as well as continuation of therapy after a dose is held beyond 3 days, must be discussed with the Medical Monitor.

### 6.7.1 Renal Impairment

After administration of a single 100 mg radiolabeled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine (2% acalabrutinib). No clinically relevant pharmacokinetic (PK) difference was observed in subjects with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR]  $\geq 30$  mL/min/1.73 m<sup>2</sup>, as estimated by Modification of Diet in Renal Disease [MDRD] equation). Acalabrutinib PK and clinical safety has not been evaluated in subjects with severe renal impairment (eGFR  $< 29$  mL/min/1.73 m<sup>2</sup>, MDRD) or renal impairment requiring dialysis.

The effect of dialysis on acalabrutinib plasma concentrations has not been studied. Acalabrutinib is rapidly absorbed, metabolised and distributed. The plasma protein binding is 97.5% and is noncovalent (potentially dialyzable). However, acalabrutinib covalently binds to the target, Btk, and will not be dialyzable. As such, it is unlikely that a clinically meaningful lowering of total Btk occupancy in target cell populations will be impacted. If subjects with COVID-19 enrolled in this study require acute hemodialysis, it is recommended to dose acalabrutinib 100 mg and pause hemodialysis for 2 to 4 hours after acalabrutinib administration to allow for absorption and distribution to target cell populations.

### 6.7.2 Hepatic Impairment

Acalabrutinib clinical safety has not been evaluated in patients with severe hepatic impairment. If acalabrutinib is administered to subjects with hepatic impairment, monitor subjects carefully for AEs and follow recommendation dose modifications in [Section 6.7](#).

The PK acalabrutinib in subjects with hepatic impairment has been studied. Briefly, the AUC of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (Child-Pugh class A), 1.5-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 5.3-fold in subjects with severe hepatic impairment (Child-Pugh class C) compared with subjects with normal liver function. No clinically relevant PK difference in ACP-5862 was observed in subjects with severe hepatic impairment (Child-Pugh class C) compared with subjects with normal liver function. No clinically relevant PK differences in acalabrutinib and ACP-5862 were observed in subjects with mild or moderate hepatic impairment (total bilirubin less and equal to ULN and AST greater than ULN, or total bilirubin greater than ULN and any AST) relative to subjects with normal hepatic function (total bilirubin and AST within ULN).

## **6.8 Treatment After the End of Study**

Not applicable.

## **7. DISCONTINUATION OF TREATMENT AND SUBJECT WITHDRAWAL**

### **7.1 Discontinuation of Study Treatment**

Subjects may discontinue study treatment for the following reasons:

- Unable to swallow pills
- Completed treatment
- Pregnancy
- AE
- Investigator's decision
- Subject's withdrawal of consent from study
- Decision by the Sponsor to terminate the study
- Lost to follow-up
- Death
- Other

The Investigator should instruct the subject to contact the site before or at the time if study treatment is stopped. A subject that decides to discontinue study treatment will always be asked about the reason(s) and the presence of any AEs. The date of last intake of study treatment should be documented in the eCRF. Refer to the guidance in [Section 6.5.3](#).

All subjects will be followed through 90 ( $\pm$  7) days after randomization.

Subjects who receive acalabrutinib should have follow up assessments for safety 28 ( $\pm$  3) days after the last dose of acalabrutinib (whether due to discontinuation or completion of dosing). Telemedicine is recommended for capturing adverse events and concomitant medications. Safety laboratory tests can be done at the hospital or a local laboratory provided the results are ultimately captured in the clinical database for the study.

## **7.2 Subject Withdrawal from the Study**

A subject may withdraw from the study (eg, withdraw consent), at any time (investigational product **and** assessments) at his/her own request, without prejudice to further treatment.

A subject who considers withdrawing from the study must be informed by the Investigator about modified follow-up options (eg, telephone contact, a contact with a relative or treating physician, or information from medical records).

If the subject withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a subject withdraws from the study, he/she may request destruction of any samples taken, and the Investigator must document this in the site study records.

A subject who withdraws consent will always be asked about the reason(s) and the presence of any AE. The Investigator will follow up subjects as medically indicated.

## **7.3 Lost to Follow-Up**

A subject will be considered lost to follow-up if he/she fails to return for scheduled visits or is unable to be contacted by the study site

In the case a subject is lost to follow-up, every possible effort must be made by the study site personnel to contact the subject and determine the reason for discontinuation. Site personnel should check hospital records and a publicly available death registry (if available), as well as checking with the subject's current physician, to obtain a current survival status. The measures taken to follow up must be documented (the applicable eCRF modules will be updated).

When a subject withdraws before completing the study, the reason for withdrawal must be documented in the eCRF and in the source documents. Subjects who withdraw consent should still be encouraged to complete the SFU assessments before withdrawing consent, but these assessments cannot be mandated once consent is withdrawn.

Subjects who are withdrawn or removed from study treatment will not be replaced.

## **8. STUDY ASSESSMENTS AND PROCEDURES**

Study procedures and their timing are summarised in the SoA in [Section 1.1](#).

The Investigator will ensure that data are recorded on the eCRF.

The Investigator ensures the accuracy, completeness, and timeliness of the data recorded and of the provision of answers to data queries per the Clinical Study Agreement. The Investigator will sign the completed eCRF. A copy of the completed eCRF will be archived at the study site.

Immediate safety concerns should be discussed with the Medical Monitor upon occurrence or awareness to determine if the subject should continue or discontinue study treatment.

Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential subjects meet all eligibility criteria. The Investigator will maintain a screening log to record details of all subjects screened and to confirm eligibility or record reasons for screening failure, as applicable.

### **8.1 Screening Assessments**

#### **8.1.1 Informed Consent**

The informed consent process must be followed per local and institutional guidelines ([Appendix A 3](#)).

Procedures conducted as part of the subject's clinical management of COVID-19 symptoms and obtained before signing of the ICF may be used for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within 24 hours of signing the informed consent.

#### **8.1.2 Demographics**

The following subject demographics will be collected: age, sex, race, ethnicity, and history of substance abuse (cigarettes [yes/no; if yes, specify packs per day], vaping [yes/no], recreational drugs [yes/no; if yes, specify name], alcohol [yes/no; if yes, specify amount]).

#### **8.1.3 Confirmation of Eligibility**

Subject eligibility for enrollment will be assessed per [Section 5](#).

#### **8.1.4 Medical History**

Collect and record the subject's relevant medical history through review of medical records and by interview. Concurrent medical signs and symptoms must be documented to establish baseline severities. Information on COVID-19 epidemiology will also be collected.

#### **8.1.5 Physical Examinations and Chest Imaging, Electrocardiogram, and Echocardiogram**

The screening physical examination will be symptom-directed and include height, weight and lung auscultation.

Per standard of care, chest imaging can be done by chest x-ray or CT scan with contrast, or any other appropriate means to confirm pneumonia at screening. Post treatment assessment will continue as clinically indicated.

A single 12-lead ECG and will be done at screening and at Day 10 or upon discharge from the hospital. ECG should be collected during the treatment period, as clinically indicated. For all ECGs, details of rhythm, ECG intervals, and an overall evaluation will be recorded.

An echocardiogram should be collected at baseline or during the treatment period, as clinically indicated per SoA. Percentage left ventricular ejection fraction should be recorded.

If the Investigator considers an abnormal ECG or echocardiogram finding at screening or baseline to be clinically significant, that finding should be reported as a concurrent condition.

Any clinically significant abnormal ECG or echocardiogram findings during the treatment period should be recorded in the source document and the AE section of eCRF, according to standard AE collection and reporting processes.

#### **8.1.6 Vital Signs**

The vital signs to be collected are blood pressure, respiratory rate, oximetry, pulse, and body temperature.

The oxygen-haemoglobin saturation of the blood will be assessed using standard pulse oximetry or by arterial blood gas for those subjects who have an arterial blood gas obtained.

#### **8.1.7 Urine or Serum Pregnancy**

Screening pregnancy testing will be done on women of childbearing potential only (refer to [Appendix F](#)).

### 8.1.8 Laboratory Tests

The following laboratory tests will be done as specified in the SoA ([Table 1](#)) using the sites local laboratories:

- Hematology studies must include complete blood count (CBC) with differential including, but not limited to white blood cell count, hemoglobin, platelet count, ANC or percentage, red blood cell count, absolute monocyte count or percentage, and absolute lymphocyte count (ALC) or percentage.
- Chemistry will include albumin, alkaline phosphatase, ALT, AST, bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), magnesium, phosphate/phosphorus, potassium, sodium, total bilirubin (direct and indirect bilirubin, if available), total protein, and uric acid.
- Arterial blood gases (if available)
- Serum ferritin, CRP, fibrinogen, D-dimer, procalcitonin
- Prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR)
- Hepatitis serology
- Cardiac troponin I and brain natriuretic peptide (BNP)
- SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) viral test

Samples will be collected as specified in the SoA ([Table 1](#)) and sent to a central laboratory for the following laboratory tests:

- Correlative samples (at select centers only)
- Cytokine/chemokine panel: markers include, but is not limited to,  $\text{INF}\gamma$ ,  $\text{TNF}\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-18, IL-10, and MCP-1 (at select centers only)
- Immunophenotyping: Flow cytometry testing of peripheral blood will include, but is not limited to, CD3+, CD4+, CD8+, CD14+, CD19+ and CD16+/56+ cells (at select centers only)
- SARS-CoV-2 quantitative serology and viral load/viral shedding (at ALL centers)

Refer to the laboratory manual for instructions on processing and shipping. Additional handling information provided in [Appendix C](#).

## 8.2 Concomitant Medications

Document all concomitant medications and procedures from the start of screening procedures through the end of participation on the study (refer to [Table 1](#)). Reason for treatment should be captured as “disease under study”.

Medications used as BSC should be captured as concomitant medications.

### 8.3 On-study Procedures

Planned time points for all on-study procedures are provided in the SoA ([Table 1](#)). Study Day 1 through Day 10 are considered the “on-study” days. The date of admission and discharge will be collected for all subjects. If a subject is discharged prior to Day 10, subject should continue to take acalabrutinib at home and return to the clinic per visit schedule outlined in SoA (refer to [Table 1](#) and [Section 7.1](#)).

The following laboratory evaluations will be done at the local laboratories:

- Haematology studies must include complete blood count (CBC) with differential including, but not limited to white blood cell count, hemoglobin, platelet count, ANC or percentage, red blood cell count, absolute monocyte count or percentage, and absolute lymphocyte count (ALC) or percentage.
- Chemistry will include albumin, alkaline phosphatase, ALT, AST, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, magnesium, phosphate/phosphorus, potassium, sodium, total bilirubin (direct and indirect bilirubin, if available), total protein, and uric acid.
- Arterial blood gases (if available)
- Serum ferritin, CRP, fibrinogen, D-dimer, procalcitonin
- PT, aPTT, INR
- Cardiac troponin I and BNP
- Hepatitis B serology will be collected as clinically indicated for subjects with a known history of hepatitis B exposure (see [Section 6.6.3](#))

Samples (plasma, serum, whole blood, peripheral blood mononuclear cells) will be collected per the timepoints delineated in [Table 1](#) and sent to respective central laboratories for the following tests:

- Correlative samples (at select centers only)
- Cytokine/chemokine panel: markers include, but is not limited to,  $\text{INF}\gamma$ ,  $\text{TNF}\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-18, IL-10, and MCP-1 (at select centers only)
- Immunophenotyping: Flow cytometry testing of peripheral blood will include, but is not limited to, CD3+, CD4+, CD8+, CD14+, CD19+ and CD16+/56+ cells (at select centers only)
- SARS-CoV-2 quantitative serology and viral load/viral shedding (at ALL centers)
- Acalabrutinib PK samples (at ALL centers)
- Acalabrutinib pharmacodynamic samples (at ALL centers)

Refer to the laboratory manual for instructions on processing and shipping. Additional handling information provided in [Appendix C](#).

## **8.4 Clinical Assessments During Hospitalization**

### **8.4.1 Oxygen Treatments and Ventilator Use**

If a subject requires oxygen supplementation, data will be recorded, including method of oxygen supplementation, maximum daily flow rate and fraction of inspired oxygen [FiO<sub>2</sub>].

If a subject requires mechanical ventilation, data will be recorded regarding whether ventilator weaning was attempted.

For subjects on mechanical ventilation the following ventilator settings will be recorded: tidal volume, FiO<sub>2</sub>, peak airway pressure over the last 24 hours, plateau pressure, positive end expiratory pressure, and respiratory rate. The data will be recorded qd, and the worst value of the day will be entered

For subjects on mechanical ventilation, an arterial blood gas (pH, partial pressure of oxygen [PaO<sub>2</sub>], partial pressure of carbon dioxide [PaCO<sub>2</sub>], and FiO<sub>2</sub> at the time the sample was obtained), if available, will be recorded qd. If more than one value is obtained for the arterial blood gases, the value closest to 08:00 will be used.

Predicted body weight will be recorded on the ventilator eCRF for assessment of tidal volume.

### **8.4.2 Modified Sequential Organ Failure Assessment (SOFA) Scores**

A modified SOFA score will be calculated. For each of the following routine assessments, the worst value of the day will be recorded in the eCRF: PaO<sub>2</sub>/FiO<sub>2</sub> (mmHg) or oxygen saturation by pulse oximetry (SpO<sub>2</sub>)/FiO<sub>2</sub> (mmHg), platelet count, bilirubin, vasopressor use (µg/kg/min, mmHg), and creatinine ([or urine output]). For laboratory values, use last available (if within 48 hours). On days when laboratory results are unavailable, values will be extrapolated from the previously available values.

### **8.4.3 Assessment of Number of Days in ICU**

Assessment of ICU length of stay will be obtained by asking the Investigator to determine if the patient is receiving ICU standard care (or equivalent) on each day during hospitalization up to Day 90. In the event of an affirmative response, a further question will be asked to determine if this ICU care is considered necessary (rather than being due to logistical reasons).

Only days in the ICU (or equivalent), which the Investigator considers necessary, will be regarded as ICU days.

## **8.5 Follow Up Procedures**

Follow up procedures are outlined in [Section 1.1](#)

## 8.6 Collection of Adverse Events

The Principal Investigator is responsible for ensuring that all staff involved in the study are familiar with the content of this section.

The definitions of an AE or SAE can be found in [Appendix B](#).

The following are NOT considered an AE:

- **Pre-existing condition that has not worsened:** A pre-existing condition (documented on the medical history eCRF) is not considered an AE unless the severity, frequency, or character of the event worsens during the study period.
- **Diagnostic testing and procedures:** Testing and procedures should not be reported as AEs or SAEs, but rather the cause for the test or procedure should be reported. If a test or procedure is done to rule out a diagnosis, the sign or symptom leading to the test/procedure should be the event term, and the event term should only be updated to the diagnosis if/when the diagnosis is confirmed. Testing and procedures performed solely as screening measures (eg, routine screening mammography or colonoscopy) should not be reported as AEs or SAEs.
- **Abnormal laboratory results:** Abnormal laboratory results are not AEs unless they are clinically significant. For example, a clinically significant laboratory result is one that requires treatment (for example a blood transfusion for low haemoglobin) or requires a change in study drug (eg, lowering the dose or withholding study drug while the laboratory finding resolves or stabilizes).
- **Progression of underlying disease:** Progression of underlying disease related to COVID-19 pneumonia (such as worsening of respiratory status or complications associated with pneumonia) will not be reported as an AE if it is clearly consistent with the suspected progression of the underlying disease. Clinical symptoms of progression may be reported as AEs if the symptoms cannot be determined as exclusively due to the progression of the underlying disease, or if they do not fit the expected pattern of progression for the disease under study.

Symptomatic deterioration may occur in some subjects. Symptomatic deterioration is when progression is evident in the subject's clinical symptoms and the Investigator may elect not to perform further disease assessments.

If there is any uncertainty about an AE being due only to the disease under study, it should be reported as an AE or SAE.

AE will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or the subject's legally authorized representative).

The Investigator and any designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE. For information on how to follow up AEs see [Section 8.6.3](#).

### **8.6.1 Method of Detecting AEs and SAEs**

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about AE occurrences.

### **8.6.2 Time Period and Frequency for Collecting AE and SAE Information**

After the signing of the ICF, all SAEs must be reported. After the first dose of study treatment, all AEs/SAEs, irrespective of attribution of causality, must be reported.

AE reporting, irrespective of seriousness, ends 28 ( $\pm$  3) days after the last dose of study treatments(s) for those on acalabrutinib + BSC (Arm 1) and 28 ( $\pm$  10) days from randomization for those on BSC only (Arm 2).

SAEs considered related to study treatments(s) or study procedures occurring after the end of the AE reporting period (as defined above) must be reported. Information on concomitant medications at the time of the treatment-related SAE will also be collected.

All SAEs will be recorded and reported to the Sponsor or designee within 1 day (ie, immediately but **no later than 24 hours** from when he or she becomes aware of it), as indicated in [Appendix B](#). The Investigator will submit any updated SAE data to the Sponsor within 24 hours of it being available.

The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for reporting SAEs are provided in [Section 8.7.1](#).

### **8.6.3 Follow-up of AEs and SAEs**

After the initial AE/SAE report, the Investigator is required to proactively follow each subject at subsequent visits/contacts. All SAEs/non-SAEs/AEs of special interest (AESIs; as defined in [Section 8.6.12](#)), will be followed until resolution, stabilization, the event is otherwise explained, or the subject is lost to follow-up.

Any AEs that are unresolved at the subject's last AE assessment or other assessment/visit as appropriate in the study are followed up by the Investigator for as long as medically indicated, but without further recording in the eCRF. The Sponsor retains the right to request additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.

### **8.6.4 Adverse Event Data Collection**

The following variables will be collected for each AE:

- AE diagnosis/description

- The date when the AE started and stopped
- Maximum Common Terminology Criteria for Adverse Events (CTCAE) grade
- Whether the AE is serious or not
- Investigator causality rating against the investigational product (yes or no)
- Action taken regarding investigational product
- Administration of treatment for the AE
- Outcome

In addition, the following variables will be collected for SAEs:

- Date AE met criteria for SAE
- Date Investigator became aware of SAE
- Seriousness criteria
- Date of hospitalisation
- Date of discharge
- Probable cause of death
- Date of death
- Autopsy performed
- Causality assessment in relation to study procedure(s)
- Causality assessment to other medications
- Description of SAE

The grading scales found in the revised NCI CTCAE Version 5.0 will be utilized for all events with an assigned CTCAE grading. For those events without assigned CTCAE grades, the recommendation in the CTCAE criteria that converts mild, moderate, and severe events into CTCAE grades should be used. A copy of the CTCAE Version 5.0 can be downloaded from the Cancer Therapy Evaluation Program website (<http://ctep.cancer.gov>).

#### **8.6.5 Causality Collection**

The Investigator will assess causal relationship between investigational product and each AE, and answer 'yes' or 'no' to the question 'Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?'

For SAEs, causal relationship will also be assessed for other medication and study procedures. Note that for SAEs that could be associated with any study procedure the causal relationship is implied as 'yes'.

A guide to the interpretation of the causality question is found in [Appendix B](#) of this protocol.

### **8.6.6 Adverse Events Based on Signs and Symptoms**

All AEs spontaneously reported by the subject or reported in response to the open question from the study site staff: *'Have you had any health problems since the previous visit/you were last asked?'*, or revealed by observation will be collected and recorded in the eCRF. When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.

### **8.6.7 Adverse Events Based on Examinations and Tests**

The results from the protocol-mandated laboratory tests and vital signs will be summarised in the Clinical Study Report. Deterioration as compared to baseline in protocol-mandated procedures (eg, safety laboratory tests and vital signs) should therefore only be reported as AEs if they fulfil any of the SAE criteria or are the reason for discontinuation of treatment with the investigational product.

If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result/vital sign will be considered as additional information. Wherever possible the reporting Investigator uses the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value). In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-mandated parameters should be reported as AE(s).

Deterioration of a laboratory value, which is unequivocally due to disease progression, should not be reported as an AE/SAE.

Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study, see [Section 8.6.9](#) and [Section 8.6.10](#).

### **8.6.8 Hy's Law**

Cases where a subject shows elevations in liver biochemistry may require further evaluation, and occurrences of AST or ALT  $\geq 3 \times \text{ULN}$  together with total bilirubin  $\geq 2 \times \text{ULN}$  may need to be reported as SAEs. Please refer to [Appendix D](#) for further instruction on cases of increases in liver biochemistry and evaluation of Hy's law.

### **8.6.9 Disease Under Study**

Systemic symptoms of the disease under study are those which might be expected to occur as a direct result of the clinical presentation associated with COVID-19 pneumonia and respiratory illness. Events which are unequivocally due to disease under study should not be

reported as an AE during the study unless they meet SAE criteria or lead to discontinuation of the investigational product.

#### **8.6.10 Disease Progression**

Disease progression can be considered as a worsening of a subject's condition attributable to COVID-19 pneumonia and respiratory illness for which the investigational product is being studied. It may be an increase in the severity of the disease under study and/or increases in the symptoms of the disease. Events, which are unequivocally due to COVID-19 pneumonia and respiratory illness, should not be reported as an AE or SAE during the study. Events attributable to disease progression of COVID-19 include pulmonary failure, ARDS, sepsis, shock, multiorgan failure and death.

#### **8.6.11 Deaths**

All deaths that occur during the study treatment period, or within the protocol-defined follow up period after the administration of the last dose of study treatment, must be reported as follows:

- Death clearly resulting from disease progression should be documented in the eCRF in the Death page. It should not be reported as an SAE.
- Where death is not due (or not clearly due) to progression of the disease under study, the AE causing the death must be reported as an SAE within 24 hours. It should also be documented in the Death page in the eCRF. The report should contain a comment regarding the co-involvement of disease progression, if appropriate, and should assign the main and contributory causes of death.
- Deaths with an unknown cause should always be reported as an SAE and documented in the Death page in the eCRF, but every effort should be made to determine a cause of death. A post-mortem may be helpful in the assessment of the cause of death, and if performed, a copy of the post-mortem results should be forwarded to Sponsor Patient Safety or its representative within the usual time frames.

Deaths occurring after the protocol-defined follow-up period after the administration of the last dose of study treatment should be documented in the Death page. If the death occurred as a result of an event that started after the defined follow-up period and the event is considered to be due to a late-onset toxicity to study treatment, then it should also be reported as an SAE.

#### **8.6.12 Adverse Events of Special Interest**

AESIs are events of scientific and medical interest specific to the further understanding of the acalabrutinib safety profile and require close monitoring and rapid communication by the Investigators to the Sponsor. An AESI can be serious or non-serious. All AESIs will be recorded in the eCRF. Serious AESIs will be recorded and reported as per [Section 8.7.1](#).

The following events are AESIs for subjects receiving acalabrutinib and must be reported to the Sponsor expeditiously (see [Section 8.7.1](#) for reporting instructions), irrespective of regulatory seriousness criteria or causality:

- **Ventricular arrhythmias** (eg, ventricular extrasystoles, ventricular tachycardia, ventricular arrhythmia, ventricular fibrillation)

## **8.7 Safety Reporting and Medical Management**

### **8.7.1 Reporting of Serious Adverse Events**

All SAEs have to be reported to the Sponsor, whether or not considered causally related to the investigational product, or to the study procedure(s). All SAEs will be recorded in the eCRF. Prompt notification by the Investigator to the Sponsor of an SAE is essential so that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a study treatment under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study treatment under clinical investigation. The Sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), and Investigators.

If any SAE occurs in the course of the study, then Investigators or other site personnel inform the appropriate Sponsor representatives within 1 day (ie, immediately but **no later than 24 hours** from when he or she becomes aware of it).

The designated Sponsor representative works with the Investigator to ensure that all the necessary information is provided to the Sponsor Patient Safety data entry site **within 1 calendar day** of initial receipt for fatal and life-threatening events and **within 5 calendar days** of initial receipt for all other SAEs.

For fatal or life-threatening AEs where important or relevant information is missing, active follow-up is undertaken immediately. Investigators or other site personnel inform Sponsor representatives of any follow-up information on a previously reported SAE within 1 calendar day (ie, immediately but **no later than 24 hours** from when he or she becomes aware of it).

For all studies except those utilizing medical devices, Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to Investigators as necessary.

An Investigator who receives an Investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAEs) from the Sponsor will review and file the

report/information with the Investigator's Brochure and will notify the IRB/IEC according to local requirements, if appropriate.

For further guidance on the definition of a SAE, see [Appendix B](#).

### **8.7.2 Pregnancy**

All pregnancies, partner pregnancies, and outcomes of pregnancy/partner pregnancy should be reported to the Sponsor, with the exception of any pregnancy that is discovered before the subject has received any study treatment.

If a pregnancy is reported, the Investigator should inform the Sponsor within 1 day (ie, immediately but no later than 24 hours of when he/she becomes aware of the pregnancy).

Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

#### **8.7.2.1 Maternal Exposure**

If a subject becomes pregnant during the course of the study, investigational product should be discontinued immediately.

Pregnancy itself is not regarded as an AE unless there is a suspicion that the investigational product under study may have interfered with the effectiveness of a contraceptive medication. Congenital abnormalities/birth defects and spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs. The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) should be followed up and documented even if the subject was discontinued from the study.

If any pregnancy occurs in the course of the study, then the Investigator or other site personnel informs the appropriate Sponsor representatives within 1 day (ie, immediately but no later than 24 hours of when he/she becomes aware of the pregnancy).

The designated Sponsor representative works with the Investigator to ensure that all relevant information is provided to the Sponsor subject safety data entry site within either 1 day or 5 calendar days for SAEs (see [Section 8.7.1](#)), and within 30 days for all other pregnancies.

The same timelines apply when outcome information is available.

#### **8.7.2.2 Paternal Exposure**

Male patients should refrain from fathering a child or donating sperm during the study and for 2 days after the last dose of acalabrutinib.

Pregnancy of a subject's partner is not considered to be an AE. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality), occurring from the date of the first dose until 2 days after the last dose of acalabrutinib, should, if possible, be followed up and documented in the Pregnancy Report Form. Consent from the partner must be obtained before the Pregnancy Report Form is completed.

Where a report of pregnancy is received, prior to obtaining information about the pregnancy, the Investigator must obtain the consent of the subject's partner. The local study team should adopt the Master Pregnant Partner Form in line with local procedures/requirements and submit it to the relevant regulatory authority/institutional review board/ethics committee prior to use.

### **8.7.3 Overdose**

Study drug overdose is the accidental or intentional use of the drug in an amount higher than the dose being studied. An overdose or incorrect administration of study treatment is not an AE unless it results in untoward medical effects. Any study treatment overdose or incorrect administration of study treatment should be noted on the Overdose eCRF.

All AEs associated with an overdose or incorrect administration of study treatment should be recorded on the Adverse Event eCRF. If the associated AE fulfils serious criteria, the event should be reported to the Sponsor immediately (ie, no later than 24 hours after learning of the event).

For overdoses associated with a SAE, the standard reporting timelines apply; see [Section 8.6.2](#). For other overdoses, reporting must occur within 30 days.

The designated Sponsor representative works with the Investigator to ensure that all relevant information is provided to the Sponsor Patient Safety data entry site.

### **8.7.4 Medication Error**

If a medication error occurs in the course of the study, then the Investigator (or other site personnel) informs the appropriate Sponsor representatives within 1 day (ie, immediately but no later than 24 hours of when the Investigator (or other site personnel) becomes aware of the error.

The designated Sponsor representative works with the Investigator to ensure that all relevant information is completed within 1 calendar day (in the event of initial fatal/life-threatening errors or follow-up fatal/life-threatening errors) or 5 calendar days (in the event of other serious initial and follow-up errors) if there is an SAE associated with the medication error (see [Section 8.7.1](#)), and within 30 days for all other medication errors.

The definition of a Medication Error can be found in [Appendix B](#).

## **9. STATISTICAL CONSIDERATIONS**

### **9.1 Statistical Hypotheses**

Overall study design is described in [Section 4.1](#) of the protocol. Subjects who are hospitalized for COVID-19 symptoms and meet the eligibility criteria will be randomized 1:1 to receive acalabrutinib plus BSC (Arm 1: n=70) vs BSC (Arm 2: n=70).

Stratification by age ( $\geq 65$  vs  $< 65$  years) and comorbidities (present vs absent) will be applied to randomization.

The primary hypothesis of the study is to compare the efficacy of acalabrutinib plus BSC (Arm 1) vs BSC (Arm 2), as measured by the proportion of subjects who are alive and free of respiratory failure at Day 14:

$H_0$ :  $p_1 = p_2$  (there is no difference between Arms 1 and 2)

$H_1$ :  $p_1 \neq p_2$  (there is a difference between Arms 1 and 2)

### **9.2 Sample Size Determination**

The planned total number of subjects in this study is 140. The sample size for this study is driven by the primary efficacy endpoint.

The sample size of 140 allows for at least 85% power, with a 2-sided type 1 error of 0.05 to detect a difference of 20% between the 2 arms for the primary endpoint, assuming the proportion of subjects who are alive and free of respiratory failure at Day 14 to be 70% for BSC and 90% for acalabrutinib + BSC. The assumed proportion of subjects who are alive and free of respiratory failure at Day 14 of 70% under BSC is based on the reported rate of deaths and need for ICU admission (a surrogate for respiratory failure) in subjects who are hospitalized for COVID-19 ([CDC 2020](#); [Arentz 2020](#); [Bhatraju 2020](#); [Grasselli 2020](#)).

### **9.3 Populations for Analyses**

The analysis populations are defined as shown in [Table 4](#).

**Table 4 Analysis Populations**

<b>Population/ Analysis set</b>	<b>Description</b>
Full analysis set (ITT population)	The full analysis set will include all subjects who are randomized and will be used for all efficacy analyses. Treatment arms will be compared on the basis of randomized study treatment, regardless of the treatment actually received. Patients who were randomized but did not subsequently go on to receive study treatment will be included in the analysis in the treatment arm to which they were randomized, following the “intent-to-treat” principle.
Per-protocol analysis set	The per-protocol analysis set will be a subset of the ITT population including only patients without important detected protocol deviations affecting the efficacy endpoints. Patients will be summarised according to the actual treatment first received. The primary endpoint of the study will also be summarized for this population.
Safety analysis set	The safety analysis set (Safety population) is based on the treatment subjects actually received. In this study, the treatment is either acalabrutinib + BSC or BSC only. If a subject receives at least 1 dose of acalabrutinib, the subject is considered as acalabrutinib-treated, regardless which arm the subject was randomized to. Subjects who are randomized to acalabrutinib + BSC but do not receive any acalabrutinib will be summarized in the BSC group.
PK analysis set	The PK analysis set will include all subjects who receive $\geq 1$ dose of acalabrutinib and had $\geq 1$ post-dose evaluable PK data point for acalabrutinib. The population will be defined by AstraZeneca, the pharmacokineticist and the statistician prior to any analyses being performed.

BSC = best supportive care; ITT = Intent-to-treat; PK = pharmacokinetic.

## 9.4 Interim Analysis

There are no formal interim futility and interim efficacy analyses in this Phase 2 study.

## 9.5 Missing Data Handling

No imputation of values for missing data will be performed except that missing or partial start and end dates for AEs and concomitant medication will be imputed per prespecified, conservative imputation rules.

The specification for handling death in the analysis of endpoints that do not contain mortality as a component will be provided in the Statistical Analysis Plan (SAP).

## **9.6 Statistical Analyses**

A comprehensive SAP will be developed and finalized before database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. Any deviations from the SAP will be reported in the Clinical Study Report.

### **9.6.1 Safety Analyses**

Safety assessments will consist of monitoring and recording AEs, SAEs and AEs leading to discontinuation of study treatment; measurements of protocol-specified hematology, clinical chemistry, and other laboratory variables; measurement of protocol-specified vital signs; and other protocol-specified tests that are deemed critical to the safety evaluation of the study treatment. All safety analyses will be performed on the safety analysis set as defined in [Section 9.3](#).

Verbatim descriptions of AEs will be mapped per the most recent version of Medical Dictionary for Regulatory Activities (MedDRA) thesaurus terms and graded per National Cancer Institute (NCI) CTCAE, v5.0 or higher. Extent of exposure to study treatment, all AEs, SAEs, any AEs leading to study treatment discontinuation, and study treatment related AEs will be summarized. The frequency of AEs will be summarized by system organ class and preferred terms per MedDRA by the worst reported NCI CTCAE grade. TEAEs will be summarized, unless otherwise specified. In this study, for Arm 1 (acalabrutinib + BSC), TEAEs are defined as AEs starting or ongoing AEs worsening after the first dose of study treatment and AEs with start date up to the last dose of study treatment plus 28 ( $\pm$  3) days; for Arm 2 (BSC only), TEAEs are defined as AEs starting or ongoing AEs worsening after the date of randomization and AEs with start date up to 28 ( $\pm$  10) days from randomization.

Laboratory abnormalities will be defined based on laboratory normal ranges (universal normal ranges, if central lab). Selected laboratory parameters may be analysed with shift tables and summaries of changes from baseline to worst post-treatment value.

Vital sign and all other safety assessments will be tabulated and summarized.

Full details of AE, laboratory assessments, vital sign assessments and all other safety assessments will be provided in the SAP.

## 9.6.2 Efficacy Analyses

### Primary Endpoint

The primary endpoint is the proportion of subjects who are alive and free of respiratory failure at Day 14 (see [Section 3](#) for a definition of respiratory failure). The point estimate and its 95% confidence interval (CI; using Blyth Still Casella method) will be calculated for each treatment arm. The Cochran-Mantel-Haenszel  $\chi^2$  test stratified by age ( $\geq 65$  vs  $< 65$  years) and comorbidities (present vs absent) will be used to compare the proportion of subjects who are alive and free of respiratory failure at Day 14 between the two treatment arms. An unstratified analysis will also be performed. Finally, the difference in the proportion of subjects who are alive and free of respiratory failure at Day 14 will also be provided with 95% CIs.

The primary endpoint of the study will be summarized by subgroups that include age group, country, sex, race, ethnicity, comorbidities, and history of substance abuse.

The primary endpoint will be summarized and analysed as per the methods above for the full analysis set (ITT population) as well as the per-protocol analysis set.

Additional sensitivity analyses and subgroup analyses of the primary endpoint may be performed as appropriate.

### Secondary Endpoints

The proportion of subjects alive and free of respiratory failure at Day 28 will be summarized using the full analysis set.

Summary statistics (n, mean, median, standard deviation, minimum, and maximum) will be presented by treatment arm for continuous secondary efficacy endpoints (refer to [Section 3](#)). Summary statistics for the number of days hospitalized from randomization to 28 days after randomization and the number of days in ICU from randomization to 28 days after randomization will be summarised.

Time from randomization to first occurrence of respiratory failure or death on study (up to 28 days after randomization) due to any cause will be analysed using Kaplan-Meier method; hazard ratio and corresponding 95% CIs will be estimated using Cox proportional hazards models, stratified by randomisation stratification factors. If a subject did not have an event and did not drop out prior to Day 28, the data will be censored at Day 28; if a subject did not have an event but dropped out prior to Day 28, the data will be censored at the last date known to be alive and free of respiratory failure.

The statistical analysis plan will provide the further details.

### 9.6.3 Pharmacokinetic and Pharmacodynamic Analyses

The statistical analysis and reporting of PK and pharmacodynamic parameters will be provided in the SAP.

## 10. REFERENCES

Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19.

Bhatraju PK, Ghassemiah BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med. 2020 Mar 30.

Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31:119-132.

Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;274:323-32.

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR. 2020;69:343-6.

Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19:181-93.

Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529-39.

Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020; In Press.

Covey T, Gulranjani M, Cheung J, et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study. Blood. 2017;130(Supplement 1):1741.

Florence JM, Krupa A, Booshehri LM, et al. Inhibition of Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L:52-L58.

Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA*. 2020 Apr 6.

Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment. *Eur Respir J*. 2015;45:1463-78.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.

Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol*. 2005;75:185-94.

Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. *J Med Virol*. 2020;92:424-32.

Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight*. 2019;4. pii: 123158.

Moine P, McIntyre R, Schwartz MD, et al. NF- $\kappa$ B regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. *Shock*. 2000;13:85-91.

O’Riordan CE, Purvis GSD, Collotta D, et al. Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice. *Front Immunol*. 2019 Sep 6;10:2129. doi: 10.3389/fimmu.2019.02129.

Page TH, Urbaniak AM, Espirito Santo AI, et al. Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor- $\kappa$ B recruitment. *Biochem Biophys Res Commun*. 2018;499:260-266.

Sun CCL, Nierman PK, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. *Blood*. 2020 Mar 20. [Epub ahead of print].

Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. *Blood*. 2020 Apr 17. pii: blood.2020006288. doi: 10.1182/blood.2020006288. [Epub ahead of print].

Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol*. 2004;136:95-103.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Feb 24.

Yoshikawa T, Hill T, Li K, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. *J Virol*. 2009;83:3039-48.

Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. *Proc Natl Acad Sci U S A*. 2014;111:4970-5.

Zhao J, Zhao J, Van Rooijen N, et al. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-COV-infected mice. *PLoS Pathog*. 2009;5:31000636.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054-62.

## **Appendix A      Regulatory, Ethical and Study Oversight Considerations**

### **A 1      Regulatory and Ethical Considerations**

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
- Applicable International Council for Harmonisation (ICH) GCP Guidelines
- Applicable laws and regulations

The protocol, protocol amendments, ICF, Investigator's Brochure, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by the Investigator, and reviewed and approved by the IRB/IEC, before the study is initiated.

Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subjects.

The Investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations

The study will be performed in accordance with the Sponsor policy on Bioethics and Human Biological Samples.

### **A 2      Financial Disclosure**

Investigators and sub-investigators will provide the Sponsor with sufficient, accurate financial information as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

### **A 3 Informed Consent Process**

The Investigator or his/her representative will explain the nature of the study to the subject or his/her legally authorised representative and answer all questions regarding the study.

Subjects must be informed that their participation is voluntary. Subjects or their legally authorised representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.

The medical record must include a statement that written informed consent was obtained before the subject was enrolled in the study and the date and time the written consent was obtained. The authorised person obtaining the informed consent must also sign the ICF.

Subjects must be re-consented to the most current version of the ICF(s) during their participation in the study.

A copy of the ICF(s) must be provided to the subject or the subject's legally authorized representative.

Subjects will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the sample storage period. If a subject withdraws consent to the use of donated biological samples, the samples will be disposed of/destroyed, and the action documented. If samples already have been analysed at the time of the request, the Sponsor will not be obliged to destroy the results of this research.

### **A 4 Data Protection**

Each subject will be assigned a unique identifier by the Sponsor. Any subject records or data sets transferred to the Sponsor will contain only the identifier; subject names or any information which would make the subject identifiable will not be transferred.

The subject must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the subject.

The subject must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorised personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

## **A 5 Committee Structures**

An iDMC will be formed. Detailed information regarding the composition of the iDMC and detailed iDMC procedures will be provided in a separate charter. The iDMC will be responsible for reviewing the safety periodically and provide recommendations according to the charter.

The safety of all Sponsor clinical studies is closely monitored on an ongoing basis by Sponsor representatives in consultation with Patient Safety. Issues identified will be addressed; for example, this could involve amendments to the CSP and letters to Investigators.

## **A 6 Dissemination of Clinical Study Data**

A description of this clinical trial will be available on <http://astrazenecaclinicaltrials.com> and <http://www.clinicaltrials.gov> as will the summary of the main study results when they are available. The clinical trial and/or summary of main study results may also be available on other websites according to the regulations of the countries in which the main study is conducted.

## **A 7 Data Quality Assurance**

All subject data relating to the study will be recorded on printed CRF or eCRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF/eCRF.

The Investigator must maintain accurate documentation (source data) that supports the information entered in the CRF/eCRF.

The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

Study monitors will perform ongoing source data verification to confirm that data entered into the CRF/eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of subjects are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the

retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

## **A 8 Source Documents**

Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are filed at the Investigator's site.

Data reported on the CRF/eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

Definitions of what constitutes source data can be found in the Clinical Study Agreement.

## **A 9 Study and Site Closure**

The Sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. The study may be stopped if, in the judgment of the Sponsor, trial subjects are placed at undue risk because of clinically significant findings that:

- Meet individual stopping criteria or are otherwise considered significant
- Are assessed as causally related to study treatment,
- Are not considered to be consistent with continuation of the study

Regardless of the reason for termination, all data available for the subject at the time of discontinuation of follow-up must be recorded in the CRF/eCRF. All reasons for discontinuation of treatment must be documented.

In terminating the study, the Sponsor will ensure that adequate consideration is given to the protection of the subjects' interests.

Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The Investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines
- Inadequate recruitment of subjects by the Investigator
- Discontinuation of further study treatment development

## **A 10      Publication Policy**

The results of this study may be published or presented at scientific meetings once the primary analysis is completed and the study is unblinded. No other publications prior to that timepoint is allowed.

The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

Subsequent to the primary publication, if an Investigator plans to publish any subset of data, or case report, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.

## **Appendix B      Adverse Event Definitions and Additional Safety Information**

### **B 1      Definition of Adverse Events**

An AE is the development of any untoward medical occurrence (other than progression of the disease under evaluation) in a patient or clinical study subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, an abnormal laboratory finding), symptom (eg, nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

The term AE is used to include both serious and non-serious AEs and can include a deterioration of a pre-existing medical occurrence. An AE may occur at any time, including run-in or washout periods, even if no study treatment has been administered.

### **B 2      Definition of Serious Adverse Events**

A SAE is an AE occurring during any study phase (ie, run-in, treatment, washout, follow-up), that fulfils one or more of the following criteria:

- Results in death
- Is immediately life-threatening
- Requires in-patient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability or incapacity
- Is a congenital abnormality or birth defect
- Is an important medical event that may jeopardize the subject or may require medical treatment to prevent one of the outcomes listed above.

### **B 3      Life-threatening**

‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it occurred, or it is suspected that use or continued use of the product would result in the subject’s death. ‘Life-threatening’ does not mean that, had an AE occurred in a more severe form, it might have caused death (eg, hepatitis that resolved without hepatic failure).

### **B 4      Hospitalization**

Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons for it may be (eg, bronchospasm, laryngeal oedema). Hospital admissions and/or surgical operations planned before or during a study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.

## **B 5 Important Medical Event or Medical Treatment**

Medical and scientific judgement should be exercised in deciding whether a case is serious in situations where important medical events may not be immediately life threatening or result in death, hospitalization, disability or incapacity but may jeopardize the subject or may require medical treatment to prevent one or more outcomes listed in the definition of serious. These should usually be considered as serious.

Simply stopping the suspect drug does not mean that it is an important medical event; medical judgement must be used.

- Angioedema not severe enough to require intubation but requiring intravenous hydrocortisone treatment
- Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with N-acetylcysteine
- Intensive treatment in an emergency room or at home for allergic bronchospasm
- Blood dyscrasias (eg, neutropenia or anemia requiring blood transfusion, etc.) or convulsions that do not result in hospitalization
- Development of drug dependency or drug abuse

## **B 6 Intensity Rating Scale**

The grading scales found in the revised NCI CTCAE v5.0 will be utilized for all events with an assigned CTCAE grading. For those events without assigned CTCAE grades, the recommendation in the CTCAE criteria that converts mild, moderate and severe events into CTCAE grades should be used. A copy of the CTCAE can be downloaded from the Cancer Therapy Evaluation Program website (<http://ctep.cancer.gov>).

It is important to distinguish between serious and severe AEs. Severity is a measure of intensity whereas seriousness is defined by the criteria in [Appendix B 2](#). An AE of severe intensity need not necessarily be considered serious. For example, nausea that persists for several hours may be considered severe nausea, but not a SAE unless it meets the criteria shown in [Appendix B 2](#). On the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke but would be a SAE when it satisfies the criteria shown in [Appendix B 2](#).

## **B 7            A Guide to Interpreting the Causality Question**

When assessing causality consider the following factors when deciding if there is a 'reasonable possibility' that an AE may have been caused by the drug.

- Time Course. Exposure to suspect drug. Has the subject actually received the suspect drug? Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?
- Consistency with known drug profile. Was the AE consistent with the previous knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same pharmacological class? Or could the AE be anticipated from its pharmacological properties?
- De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose of the suspect drug?
- No alternative cause. The AE cannot be reasonably explained by another aetiology such as the underlying disease, other drugs, other host or environmental factors.
- Re-challenge experience. The Sponsor would not normally recommend or support a re-challenge.
- Laboratory tests. A specific laboratory investigation (if performed) has confirmed the relationship.

In difficult cases, other factors could be considered such as:

- Is this a recognized feature of overdose of the drug?
- Is there a known mechanism?

Causality of 'related' is made if following a review of the relevant data, there is evidence for a 'reasonable possibility' of a causal relationship for the individual case. The expression 'reasonable possibility' of a causal relationship is meant to convey, in general, that there are facts (evidence) or arguments to suggest a causal relationship.

The causality assessment is performed based on the available data including enough information to make an informed judgment. With limited or insufficient information in the case, it is likely that the event(s) will be assessed as 'not related'.

Causal relationship in cases where the disease under study has deteriorated due to lack of effect should be classified as no reasonable possibility.

## **B 8            Medication Error**

For the purposes of this clinical study a medication error is an unintended failure or mistake in the treatment process for a Sponsor study treatment that either causes harm to the subject or has the potential to cause harm to the subject.

A medication error is not lack of efficacy of the drug, but rather a human or process related failure while the drug is in control of the study site staff or subject.

Medication error includes situations where an error:

- Occurred
- Was identified and intercepted before the subject received the drug
- Did not occur, but circumstances were recognized that could have led to an error

Examples of events to be reported in clinical studies as medication errors:

- Drug name confusion
- Dispensing error, eg, medication prepared incorrectly, even if it was not actually given to the subject
- Drug not administered as indicated, for example, wrong route or wrong site of administration
- Drug not taken as indicated, eg, tablet dissolved in water when it should be taken as a solid tablet
- Drug not stored as instructed, eg, kept in the fridge when it should be at room temperature
- Wrong subject received the medication (excluding IRT errors)
- Wrong drug administered to subject (excluding IRT errors)

Examples of events that **do not** require reporting as medication errors in clinical studies:

- Errors related to or resulting from IRT - including those which lead to one of the above listed events that would otherwise have been a medication error
- Subject accidentally missed drug dose(s), eg, forgot to take medication
- Accidental overdose (will be captured as an overdose)
- Subject failed to return unused medication or empty packaging
- Errors related to background and rescue medication, or standard of care medication in open label studies, even if an AstraZeneca product

Medication errors are not regarded as AEs, but AEs may occur as a consequence of the medication error.

## **Appendix C      Handling of Human Biological Samples**

### **C 1      Chain of Custody of Biological Samples**

A full chain of custody is maintained for all samples throughout their lifecycle.

The Investigator at each center keeps full traceability of collected biological samples from the subjects while in storage at the centre until shipment or disposal (where appropriate).

The sample receiver keeps full traceability of the samples while in storage and during use until used or disposed of or until further shipment and keeps documentation of receipt of arrival.

The Sponsor will keep oversight of the entire life cycle through internal procedures, monitoring of study sites, auditing or process checks, and contractual requirements of external laboratory providers.

Samples retained for further use will be stored in the Sponsor-assigned biobanks and will be registered by the Sponsor Biobank Team during the entire lifecycle.

If required, the Sponsor will ensure that remaining biological samples are returned to the site according to local regulations or at the end of the retention period, whichever is the sooner.

### **C 2      Withdrawal of Informed Consent for Donated Biological Samples**

If a patient withdraws consent specifically to the subsequent use of donated biological samples, the samples will be disposed of/destroyed, and the action documented. If samples are already analyzed, the Sponsor is not obliged to destroy the results of this research. A general withdrawal of consent to study treatment does not imply a withdrawal of consent to subsequent analyses of biological samples. In case a patient withdraws the general informed consent and additionally wants to withdraw consent for further analyses of his/her biological samples, the patient is required to sign an opt-out.

As collection of the biological sample(s) is an integral part of the study, then the subject is withdrawn from further study participation.

The Investigator:

- Ensures subjects' withdrawal of informed consent to the use of donated samples is notified immediately to Sponsor
- Ensures that biological samples from that subject, if stored at the study site, are immediately identified, disposed of /destroyed, and the action documented
- Ensures the organization(s) holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed of/destroyed, the action documented, and the signed document returned to the study site

- Ensures that the subject and Sponsor are informed about the sample disposal.

The Sponsor ensures the organization(s) holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed of/destroyed and the action documented and returned to the study site.

### **C 3 International Airline Transportation Association Regulations on Labeling and Shipment of Biological Samples**

Air transportation of biological samples (including biohazardous materials and potentially biohazardous materials) is regulated under International Airline Transportation Association (IATA) Dangerous Goods Regulations (DGR; 61st edition [2020]) Division 6.2—Infectious Substances. The IATA DGR definition of infectious substances includes any substance that is known or reasonably expected to contain pathogens, ie, microorganisms (including bacteria, viruses, rickettsiae, parasites, fungi) or other agent, such as a proteinaceous infectious particle (prion), that can cause disease in humans or animals.

As Division 6.2 infectious substances, biological samples transported by air must be classified as Category A, Category B, or Exempt; secured in IATA-compliant packaging; and identified using the appropriate United Nations shipping number and label requirements corresponding to the species, sample type, and infectious nature of material being shipped. See [Table 5](#) for details.

Under IATA regulations, patient specimens from clinical trials will fall into Category B or Exempt. Clinical trial samples can often be packed and transported at ambient temperature. However, in cases where biological samples must be refrigerated or frozen for transport (eg, using dry ice or liquid nitrogen), additional dangerous goods specifications will apply; refer to DGR Section 3.6.2.2.3.8 (e). IATA-compliant couriers and materials should be used for transportation and packaging, and where applicable, packing should be done by IATA-certified personnel.

Transportation of biological samples by road or rail is routinely subject to local regulations requiring shipment in safe, appropriate packaging materials to contain any risk of infection or contamination at all times, in addition to the use of approved couriers. Wherever possible, compliance with IATA Instruction 650 standards for biological sample containment are encouraged for road or rail transport of patient specimens.

**Table 5 IATA Dangerous Goods Regulations Classification of Infectious Substances**

Category <sup>a</sup>	Description	Shipping instructions	UN number and labeling
Category A infectious substances	Any infectious substance transported in a form that, when exposure occurs, <sup>b</sup> is capable of causing permanent disability, life threatening disease, or fatal disease in otherwise healthy humans or animals. <i>(Examples include Ebola and Lassa fever virus.)</i>	Category A pathogens must be: <ul style="list-style-type: none"> <li>• Packed and shipped in accordance with IATA Instruction 620</li> <li>• Identified using the appropriate UN shipping number and label information</li> </ul>	<u>UN 2814</u> “Infectious substances affecting humans or both humans and animals”
			<u>UN 2900</u> “Infectious substances affecting animals only”
Category B infectious substances	Any infectious substance that does not meet the criteria for inclusion in Category A. Category B infectious substances are not in a form capable of causing permanent disability, life threatening disease, or fatal disease in otherwise healthy humans or animals when exposure occurs. <sup>b</sup> <i>(Examples include hepatitis A, B, C, D, and E viruses, and HIV types 1 and 2.)</i>	Category B pathogens must be: <ul style="list-style-type: none"> <li>• Packed and shipped in accordance with IATA Instruction 650</li> <li>• Identified using the appropriate UN shipping number and label information</li> </ul>	<u>UN 3373</u> “Biological substance, Category B”
Exempt substances	Patient specimens for which there is minimal likelihood that pathogens are present. <i>(Examples may include blood-based samples, tissue cultures, or other biological samples.)</i>	Exempt substances must be: <ul style="list-style-type: none"> <li>• Packed and shipped in accordance with requirements specified in Division 6.2, Section 3.6.2.2.3.8 of the IATA DGR <sup>a</sup></li> <li>• Identified using the appropriate label information</li> </ul>	“Exempt human specimen”
			“Exempt animal specimen”

DGR = Dangerous Goods Regulation; IATA = International Airline Transportation Association; UN = United Nations.  
Note: IATA Dangerous Goods Regulations, 61st Edition. 01 January 2020. International Air Transport Association.  
Available at: <https://www.iata.org/en/programs/cargo/dgr/download/>.

<sup>a</sup> For transport purposes, the classification of infectious substances according to risk groups was removed in the DGR 46th edition (2005). There is no direct relationship between risk groups and Categories A and B.

<sup>b</sup> Exposure occurs when an infectious substance is released outside of the protective packaging, resulting in physical contact with humans or animals.

## **Appendix D      Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy's Law**

### **D 1      Introduction**

This Appendix describes the process to be followed in order to identify and appropriately report Potential Hy's Law (PHL) cases and Hy's Law (HL) cases. It is not intended to be a comprehensive guide to the management of elevated liver biochemistries.

During the course of the study the Investigator will remain vigilant for increases in liver biochemistry. The Investigator is responsible for determining whether a subject meets potential PHL criteria at any point during the study.

All sources of laboratory data are appropriate for the determination of PHL and HL events; this includes samples taken at scheduled study visits and other visits including central and all local laboratory evaluations even if collected outside of the study visits; for example, PHL criteria could be met by an elevated ALT from a central laboratory **and/or** elevated TBL from a local laboratory.

The Investigator will also review AE data (for example, for AEs that may indicate elevations in liver biochemistry) for possible PHL events.

The Investigator participates, together with AstraZeneca clinical project representatives, in review and assessment of cases meeting PHL criteria to agree whether HL criteria are met. HL criteria are met if there is no alternative explanation for the elevations in liver biochemistry other than Drug Induced Liver Injury (DILI) caused by the Investigational Medicinal Product (IMP).

The Investigator is responsible for recording data pertaining to PHL/HL cases and for reporting SAEs and AEs according to the outcome of the review and assessment in line with standard safety reporting processes.

### **D 2      Definitions**

#### **Potential Hy's Law**

AST or ALT  $\geq 3 \times$  ULN **together with** Total Bilirubin (TBL)  $\geq 2 \times$  ULN at any point during the study following the start of study medication irrespective of an increase in alkaline phosphatase (ALP).

#### **Hy's Law**

AST or ALT  $\geq 3 \times$  ULN **together with** TBL  $\geq 2 \times$  ULN, where no other reason, other than the IMP, can be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, viral hepatitis, another drug.

For PHL and HL the elevation in transaminases must precede or be coincident with (i.e. on the same day) the elevation in TBL, but there is no specified timeframe within which the elevations in transaminases and TBL must occur.

### **D 3 Identification of Potential Hy's Law Cases**

In order to identify cases of PHL it is important to perform a comprehensive review of laboratory data for any subject who meets any of the following identification criteria in isolation or in combination:

- $ALT \geq 3 \times ULN$
- $AST \geq 3 \times ULN$
- $TBL \geq 2 \times ULN$

#### **Central laboratories being used:**

When a subject meets any of the PHL identification criteria, in isolation or in combination, the central laboratory will immediately send an alert to the Investigator (also sent to AstraZeneca representative).

The Investigator will also remain vigilant for any local laboratory reports where the PHL identification criteria are met, where this is the case the Investigator will:

- Notify the AstraZeneca representative
- Request a repeat of the test (new blood draw) by the central laboratory without delay
- Complete the appropriate unscheduled laboratory CRF module(s) with the original local laboratory test result

When the identification criteria are met from central or local laboratory results the Investigator will without delay:

- Determine whether the subject meets PHL criteria (see [Section D 2](#) within this Appendix for definition) by reviewing laboratory reports from all previous visits (including both central and local laboratory results)

#### **Local laboratories being used:**

The Investigator will without delay review each new laboratory report and if the identification criteria are met will:

- Notify the AstraZeneca representative
- Determine whether the subject meets PHL criteria (see [Section D 2](#) within this Appendix for definition) by reviewing laboratory reports from all previous visits

- Promptly enter the laboratory data into the laboratory CRF

## **D 4 Follow-up**

### **D 4.1 Potential Hy's Law Criteria not met**

If the subject does not meet PHL criteria the Investigator will:

- Inform the AstraZeneca representative that the subject has not met PHL criteria.
- Perform follow-up on subsequent laboratory results according to the guidance provided in the Clinical Study Protocol.

### **D 4.2 Potential Hy's Law Criteria met**

If the subject does meet PHL criteria the Investigator will:

- Determine whether PHL criteria were met at any study visit prior to starting study treatment
- Notify the AstraZeneca representative who will then inform the central Study Team
- Within 1 day of PHL criteria being met, the Investigator will report the case as an SAE of Potential Hy's Law; serious criteria 'Important medical event' and causality assessment 'yes/related' according to CSP process for SAE reporting.
- For subjects that met PHL criteria prior to starting IMP, the investigator is not required to submit a PHL SAE unless there is a significant change# in the subject's condition
- The Study Physician contacts the Investigator, to provide guidance, discuss and agree an approach for the study subjects' follow-up (including any further laboratory testing) and the continuous review of data
- Subsequent to this contact the Investigator will:
  - Monitor the subject until liver biochemistry parameters and appropriate clinical symptoms and signs return to normal or baseline levels, or as long as medically indicated. Completes follow-up SAE Form as required.
  - Investigate the aetiology of the event and perform diagnostic investigations as discussed with the Study Physician. This includes deciding which the tests available in the Hy's law lab kit should be used
  - Complete the three Liver CRF Modules as information becomes available

# A 'significant' change in the subject's condition refers to a clinically relevant change in any of the individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in combination, or a clinically relevant change in associated symptoms. The determination of whether there has been a significant change will be at the discretion of the Investigator; this may be in consultation with the Study Physician if there is any uncertainty.

## D 5 Review and Assessment of Potential Hy's Law Cases

The instructions in this section should be followed for all cases where PHL criteria are met.

As soon as possible after the biochemistry abnormality was initially detected, the Study Physician contacts the Investigator in order to review available data and agree on whether there is an alternative explanation for meeting PHL criteria other than DILI caused by the IMP, to ensure timely analysis and reporting to health authorities within 15 calendar days from date PHL criteria was met. The AstraZeneca Global Clinical Lead or equivalent and Global Safety Physician will also be involved in this review together with other subject matter experts as appropriate.

According to the outcome of the review and assessment, the Investigator will follow the instructions below.

**Where there is an agreed alternative explanation** for the ALT or AST and TBL elevations, a determination of whether the alternative explanation is an AE will be made and subsequently whether the AE meets the criteria for a SAE:

- If the alternative explanation is **not** an AE, record the alternative explanation on the appropriate CRF
- If the alternative explanation is an AE/SAE: update the previously submitted Potential Hy's Law SAE and AE CRFs accordingly with the new information (reassessing event term; causality and seriousness criteria) following the AZ standard processes.

If it is agreed that there is **no** explanation that would explain the ALT or AST and TBL elevations other than the IMP:

- Send updated SAE (report term 'Hy's Law') according to AstraZeneca standard processes.
  - The 'Medically Important' serious criterion should be used if no other serious criteria apply
  - As there is no alternative explanation for the HL case, a causality assessment of 'related' should be assigned.

If, there is an unavoidable delay, of over 15 calendar days in obtaining the information necessary to assess whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:

- Provides any further update to the previously submitted SAE of Potential Hy's Law, (report term now 'Hy's Law case') ensuring causality assessment is related to IMP and seriousness criteria is medically important, according to Clinical Study Protocol (CSP) process for SAE reporting.

- Continue follow-up and review according to agreed plan. Once the necessary supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are still met. Update the previously submitted PHL SAE report following CSP process for SAE reporting, according to the outcome of the review and amending the reported term if an alternative explanation for the liver biochemistry elevations is determined.

## D 6 Laboratory tests

### Hy's Law Laboratory Kit for Central Laboratories

Additional standard chemistry and coagulation tests	GGT LDH Prothrombin time INR
Viral hepatitis	IgM anti-HAV IgM and IgG anti-HBc HBsAg HBV DNA IgG anti-HCV HCV RNA* IgM anti-HEV HEV RNA
Other viral infections	IgM & IgG anti-CMV IgM & IgG anti-HSV IgM & IgG anti-EBV
Alcoholic hepatitis	Carbohydrate deficient transferrin (CD-transferrin)**
Autoimmune hepatitis	Antinuclear antibody (ANA) Anti-Liver/Kidney Microsomal Ab (Anti-LKM) Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases	alpha-1-antitrypsin Ceruloplasmin Iron Ferritin Transferrin Transferrin saturation

\* HCV RNA is only tested when IgG anti-HCV is positive or inconclusive

\*\* Carbohydrate deficient transferrin (CD-transferrin) is not available in China. Study teams should amend this list accordingly

## Reference

Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806-815.

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf>.

## Appendix E Examples of Coadministered Drugs That Need Additional Consideration

The lists of drugs in these tables are not exhaustive. Any questions about drugs not on this list should be addressed to the Medical Monitor of this study.

**Table 6 CYP3A Inhibitors**

<b>Strong inhibitors of CYP3A</b>	<b>Moderate inhibitors of CYP3A</b>
Boceprevir	aprepitant
clarithromycin <sup>a</sup>	cimetidine
cobicistat <sup>a</sup>	ciprofloxacin
conivaptan <sup>a</sup>	clotrimazole
danoprevir and ritonavir <sup>b</sup>	crizotinib
diltiazem <sup>a</sup>	cyclosporine
elvitegravir and ritonavir <sup>b</sup>	dronedarone <sup>a</sup>
grapefruit juice	erythromycin
Idelalisib	fluconazole
indinavir and ritonavir <sup>b</sup>	fluvoxamine
itraconazole <sup>a</sup>	imatinib
Ketoconazole	tofisopam
lopinavir and ritonavir <sup>a,b</sup>	verapamil <sup>a</sup>
Nefazodone	
nelfinavir <sup>a</sup>	
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir) <sup>b</sup>	
Posaconazole	
ritonavir <sup>a,b</sup>	
saquinavir and ritonavir <sup>a,b</sup>	
telaprevir <sup>a</sup>	
tipranavir and ritonavir <sup>a,b</sup>	
Troleandomycin	
Voriconazole	

<sup>a</sup> Inhibitor of P-glycoprotein.

<sup>b</sup> Ritonavir is usually given in combination with other anti-HIV or anti-HCV drugs in clinical practice. Caution should be used when extrapolating the observed effect of ritonavir alone to the effect of combination regimens on CYP3A activities.

**Table 7 CYP3A Inducers**

<b>Strong inducers of CYP3A</b>	<b>Moderate inducers of CYP3A</b>
Carbamazepine	bosentan
Enzalutamide	efavirenz
Mitotane	etravirine
Phenytoin	modafinil
Rifampin	
St. John's wort <sup>a</sup>	

<sup>a</sup> The effect of St. John's wort varies widely and is preparation-dependent.

Source: US FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers.  
<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inVivo>. Accessed 23 July 2019.

**Table 8 Other Drugs Needing Additional Considerations**

<b>Proton pump inhibitors</b>	<b>H2-receptor antagonists</b>
Dexlansoprazole	cimetidine
Esomeprazole	famotidine
Lansoprazole	nizatidine
Omeprazole	ranitidine
Rabeprazole	
Pantoprazole	

Source: US FDA. Established pharmacologic class text phrase. <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/lawsactsandrules/ucm428333.pdf>. Accessed 23 July 2019.

## **Appendix F      Contraception Requirements**

Contraception requirements for this study are as follows.

### **F 1      Female Subjects of Childbearing Potential**

Please note, females of childbearing potential are defined as those who are post-menarche, not surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.

Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all hormonal replacement therapy and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.
- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all hormonal replacement therapy, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago.

Female patients of childbearing potential who are not totally sexually abstinent (ie, refraining from heterosexual intercourse during the entire period of risk associated with study treatments), and who intend to be sexually active with a nonsterilized male partner, must use at least one highly effective method of contraception (see [Table 9](#)) consistent with local regulations regarding the use of contraception for subjects participating in clinical trials, from the time of signing the ICF throughout the total duration of the drug treatment and the drug washout period (2 days after the last dose of acalabrutinib or prednisone; or 2 months after the last dose of vincristine; or 6 months after the last dose of doxorubicin; or 12 months after the last dose of rituximab or cyclophosphamide; whichever is longest).

Non-sterilized male partners of a female patient of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. The reliability of total sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Female patients should refrain from breastfeeding throughout this period.

### **F 2      Male Subjects with a Female Partner of Childbearing Potential**

Non-sterilized male patients (including males sterilized by a method other than bilateral orchidectomy, eg, vasectomy) who are not abstinent and intend to be sexually active with a

female partner of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) from the time of screening throughout the total duration of the drug treatment and the drug washout period (2 days after the last dose of acalabrutinib). Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients should refrain from sperm donation throughout this period.

Vasectomized (ie, sterile) males are considered fertile and should still use a male condom plus spermicide as indicated above during the clinical trial.

Even if the female partner is pregnant, male patients should still use a condom, as indicated above during the clinical trial, if there is a concern about damaging the developing fetus from drug in ejaculate.

Female partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this period (see [Table 9](#)).

### F 3 Highly Effective Methods of Contraception

Highly effective methods of contraception, defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly, are described in [Table 9](#). Note that some contraception methods are not considered highly effective (eg, male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette/desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills).

**Table 9 Highly Effective Methods of Contraception (<1% Failure Rate)**

Barrier/intrauterine methods	Hormonal methods
<ul style="list-style-type: none"> <li>Copper T intrauterine device</li> <li>Levonorgestrel-releasing intrauterine system (eg, Mirena<sup>®</sup>)<sup>a</sup></li> </ul>	<ul style="list-style-type: none"> <li>Implants: Etonogestrel-releasing implants (eg, Implanon<sup>®</sup> or Norplant<sup>®</sup>)</li> <li>Intravaginal devices: Ethinylestradiol/etonogestrel-releasing intravaginal devices (eg, NuvaRing<sup>®</sup>)</li> <li>Injection: Medroxyprogesterone injection (eg, Depo-Provera<sup>®</sup>)</li> <li>Combined pill: Normal and low dose combined oral contraceptive pill</li> <li>Patch: Norelgestromin/ethinylestradiol-releasing transdermal system (eg, Ortho Evra<sup>®</sup>)</li> <li>Minipill: Progesterone based oral contraceptive pill using desogestrel: Cerazette<sup>®</sup> is currently the only highly effective progesterone-based pill</li> </ul>

<sup>b</sup> This is also considered a hormonal method.

## Appendix G Child-Pugh Score

Cirrhosis severity, as determined by the Child-Pugh score ([Pugh 1973](#)), will be recorded in the eCRF as specified in the SoAs.

The modified Child-Pugh classification of liver disease severity according to the degree of ascites by clinical exam, serum concentrations of bilirubin and albumin, prothrombin time, and degree of encephalopathy is shown in [Table 10](#). The severity of cirrhosis is classified as follows:

- Child-Pugh class A (well-compensated disease): score of 5 to 6
- Child-Pugh class B (significant functional compromise): score of 7 to 9
- Child-Pugh class C (decompensated disease): score of 10 to 15

**Table 10 Child-Pugh Classification of Cirrhosis Severity**

Parameter	Points assigned		
	1	2	3
Ascites	Absent	Slight	Moderate
Bilirubin	<2 mg/dL (<34.2 µmol/L)	2 to 3 mg/dL (34.2 to 51.3 µmol/L)	>3 mg/dL (>51.3 µmol/L)
Albumin	>3.5 g/dL (35 g/L)	2.8 to 3.5 g/dL (28 to 35 g/L)	<2.8 g/dL (28 g/L)
Prothrombin time			
Seconds over control	<4	4 to 6	>6
INR	<1.7	1.7 to 2.3	>2.3
Encephalopathy	None	Grade 1 to 2	Grade 3 to 4

INR = international normalized ratio.

## Appendix H Abbreviations

Abbreviation or special term	Explanation
AE	Adverse event
AESI	Adverse event of special interest
ALC	Absolute lymphocyte count
ALT	Alanine aminotransferase
ANC	Absolute neutrophil count
aPTT	Activated partial thromboplastin time
AST	Aspartate aminotransferase
ARDS	Acute respiratory distress syndrome
AUC	Area under the concentration-time curve
bid	Twice daily
BNP	Brain natriuretic peptide
BSC	Best supportive care
Btk	Bruton's tyrosine kinase
BUN	Blood urea nitrogen
CBC	Complete blood count
CI	Confidence interval
C <sub>max</sub>	Maximum observed concentration
COVID-19	Coronavirus disease 2019
CRF	Case report form (electronic/paper)
CRP	C-reactive protein
CSP	Clinical Study Protocol
CT	Computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CYP	Cytochrome P450
DGR	Dangerous Good Regulation
DILI	Drug-induced liver injury
DLT	Dose-limiting toxicity
ECG	Electrocardiogram
eCRF	Electronic case report form
eGFR	Estimated glomerular filtration rate
FiO <sub>2</sub>	Fraction of inspired oxygen
GCP	Good Clinical Practice
HBV	Hepatitis B virus
HL	Hy's law
IATA	International Airline Transportation Association
ICF	Informed consent form

<b>Abbreviation or special term</b>	<b>Explanation</b>
ICH	International Council for Harmonisation
ICU	Intensive care unit
iDMC	Internal Data Monitoring Committee
IEC	Independent Ethics Committee
IL	Interleukin
INR	International normalized ratio
IRB	Institutional Review Board
IRT	Interactive response technology
LDH	Lactate dehydrogenase
MCP-1	Monocyte chemoattractant protein-1
MDRD	Modification of Diet in Renal Disease
MedDRA	Medical Dictionary for Regulatory Activities
MRI	Magnetic resonance imaging
NCI	National Cancer Institute
NG	Nasogastric
NYHA	New York Heart Association
PaCO <sub>2</sub>	Partial pressure of carbon dioxide
PaO <sub>2</sub>	Partial pressure of oxygen
PCR	Polymerase chain reaction
PD-1	Programmed cell death 1
PHL	Potential Hy's law
PI3K	Phosphatidylinositol-3-kinase
PK	Pharmacokinetic(s)
PML	Progressive multifocal leukoencephalopathy
PPI	Proton-pump inhibitor
PT	Prothrombin time
qd	Once daily
RT-PCR	Reverse transcriptase-polymerase chain reaction
SAE	Serious adverse event
SAP	Statistical Analysis Plan
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SoA	Schedule of Activities
SOFA	Sequential Organ Failure Assessment
SUSAR	Suspected unexpected serious adverse reaction
TEAE	Treatment-emergent adverse event
TLR	Toll-like receptor
TNF $\alpha$	Tumor necrosis factor alpha

<b>Abbreviation or special term</b>	<b>Explanation</b>
ULN	Upper limit of normal
WHO	World Health Organization

## Appendix I Protocol Amendment History

The Protocol Amendment Summary of Changes Table for the current amendment is located directly before the Table of Contents.

### **Amendment 1 (17Apr2020)**

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

### **Overall Rationale for the Amendment:**

Changes were implemented in the protocol amendment to address the FDA comments.

Section # and Name	Description of Change	Brief Rationale
Title Page; 1.2 Synopsis	Added “open-label” to the title and changed the IND number.	Clarity
1.1 Schedule of Activities	Formatted and edited the SoA for Part 1 (Table 1) and Part 2 (Table 2) for clarity and consistency with changes made to the body of the protocol.	Clarity and consistency
2.1 Background and Study Rationale; 4.2 Scientific Rationale for Study Design	Expanded the background and study rationale sections.	To strengthen the scientific rationale.
2.2 Benefit/Risk Assessment; 4.4 Internal DMC; Appendix A5 Committee Structures	Changed from an Independent Data Monitoring Committee (IDMC) to an internal Data Monitoring Committee (iDMC) for this study. Removed reference to an interim analysis for futility.	To clarify that the Data Monitoring Committee will be internal.
1.2 Synopsis; 3 Objectives and Endpoints	Primary endpoint: Clarified the primary endpoint to read “proportion of subjects alive and free of respiratory failure” and defined respiratory failure according to the Agency’s recommendation. Also, clarified that the primary endpoint will be through Day 14 for Part 1 and through Day 28 for Part 2.  Secondary endpoints: Added the primary endpoint for Part 2 as a secondary endpoint for Part 1 and the primary endpoint for Part 1 as a secondary endpoint for Part 2. Added additional secondary endpoints for both Parts 1 and 2.  Safety and PK endpoints: Clarified the PK endpoint.	To address FDA’s comment that endpoints should be meaningful for the target population.

Section # and Name	Description of Change	Brief Rationale
	Exploratory endpoints: Revised the first exploratory objective/endpoint to only include inflammatory cytokines/chemokines. Clarified that Btk occupancy will be compared to pre-dose.	
1.2 Synopsis; 1.3 Schema; 4.1 Overall Study Design; 4.2 Scientific Rationale for Study Design; 4.3 Justification for Dose; 6.1 Treatments Administered; 9.2 Sample Size Determination;	Revised the study design so that both Parts 1 and 2 are randomized to acalabrutinib + BSC or BSC and removed reference to a historical control for Part 2.	To address FDA's comment that given the rapidly evolving treatment regimens and access, it is unlikely that a historical control will be an appropriate comparator in this setting.
	Randomization for both Parts 1 and 2 to occur 1:1 (instead of the original 2:1 randomization in Part 1).	To address FDA's comment to randomize on 1:1 basis.
	Increased treatment duration in Part 2 from 10 to 14 days.	The duration of treatment has been selected based on the expected period of hyper-immune response for patients with COVID-19 pneumonia who are moderately ill (Part 1) and for those who are severely ill (Part 2).
	Removed option to cross over.	To address FDA's comment to remove cross over.
	Removed reference to retreatment.	To address FDA's comment to remove retreatment.
	Revised the sample size for Parts 1 and 2.	To reflect revised assumption for the primary endpoint, and the fact that Part 2 is now randomized.
	Defined "present" in the context of comorbidities.	For clarity.
5.1 Inclusion Criteria for Part 1	Removed "(Arm 1 and Arm 2)" from the section header. Revised Criterion 3 to exclude biomarkers. In addition, changed COVID-19 to SARS-CoV-2 and revised this criterion to reflect that confirmation of SARS-CoV-2 must occur within 4 days of randomization (rather than within 3 weeks of study entry). The part of Criterion 3 referring to pneumonia was changed to a separate inclusion criterion and "(documented radiographically)" was added.	For clarity and to address FDA's comment to exclude biomarkers.
5.2 Inclusion Criteria for Part 2	Removed "(ICU Cohort)" from the section header.	For clarity and consistency.

Section # and Name	Description of Change	Brief Rationale
	Revised Criterion 3 to be consistent with the definition provided in Section 5.1 (Criterion 3). Added an inclusion criterion (Criterion 4) for respiratory failure.	
5.3 Exclusion Criteria for Part 1 and Part 2 (All Subjects)	Removed Criterion 2 referring to “aggressive management”.	Given FDA’s comment that this may be seen as discriminatory against patient groups due to their moral or ethical beliefs regarding goals of care.
	Added Exclusion Criteria 11, 12, and 21, and revised Criteria 13, 15, 16, and 17.	To ensure enrollment of subjects most likely to benefit from treatment.
5.4 Exclusion Criteria for Part 1 Only	Added “Only” to the section header. Revised Criterion 1 to be consistent with changes made to the inclusion criteria.	For clarity and consistency.
5.5 Exclusion Criteria for Part 2 Only	Added “Only” to the section header. Added Criterion 2 to exclude subjects who have been receiving invasive mechanical ventilation (eg, endotracheal intubation and mechanical ventilation, or ECMO) for longer than 5 days prior to randomization.	For clarity. To ensure enrollment of subjects who are likely to benefit.
5.6 Screen Failures	Added text to indicate that subjects may be rescreened.	To permit rescreening.
6.3 Measures to Minimise Bias: Randomisation and Blinding	Revised to be consistent with changes to the study design. Added sections to describe methods and procedures for assigning subjects to treatment groups, handling incorrectly enrolled or randomized subjects, and ensuring blinding.	To provide clarity regarding the methods and procedures for randomization.
6.5.3 Prohibited or Restricted Concomitant Therapy	Revised the steroids prohibition to apply to all subjects in the study and not just subjects receiving acalabrutinib. Also, specified that if an investigator determines that corticosteroids > 7.5 mg/day is required for a subject, after discussion with the medical monitor and both agree, it may be permitted.	To prevent potential imbalance between the treatment effects in the control arm versus acalabrutinib arm.
6.8 Toxicity Management Guidelines	Changed section header from “Acalabrutinib Dose Modification Guidance in the Presence of Life-Threatening COVID-19 Infection” to “Toxicity Management Guidelines”.	For clarity.

Section # and Name	Description of Change	Brief Rationale
7.1 Discontinuation of Study Treatment; 7.3 Lost to Follow-Up	Revised text for clarification.	For clarity.
8.1 Screening Assessments; 8.3 On-Study Procedures; 8.4 Clinical Assessments During Hospitalization; 8.6.2 Time Period and Frequency for Collecting AE and SAE Information; 8.7.2 Pregnancy	Edited the text in these sections for clarification. Added Section 8.4.4 (Assessment of Number of Days in ICU) to describe assessment of ICU length of stay.	For clarity and consistency.
9.1 Statistical Hypotheses; 9.6.2 Efficacy Analyses	Revised to reflect the changes made to the study design.	For consistency and clarity.
9.3 Populations for Analyses	Added a table to define the analysis populations.	For clarity.
9.4 Interim Analyses	Revised to indicate that this study will not include any formal interim futility or interim efficacy analyses.	Futility analysis removed following revision of sample size
9.5 Missing Data Handling	Specified that information on handling death in the analysis of endpoints that do not contain mortality as a component will be provided in the SAP.	For clarity.
9.6 Statistical Analyses	Specified that statistical analyses and summaries will be performed separately for Part 1 and Part 2.	For clarity.
9.6.2 Efficacy Analyses	Revised to reflect the changes made to the study endpoints.	For consistency.
9.6.3 Pharmacokinetic and Pharmacodynamic Analyses	Added “Pharmacodynamic” to the section title and specified that statistical analysis and reporting of pharmacodynamic parameters will be provided in the SAP.	For clarity.